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The centromere is an essential structure required for the faithful segregation of 
chromosomes during mitosis, a process that is significantly dysregulated in cancer. The nucleic 
acid sequences that dominate the centromeric landscape are α-satellites, arrays of 171 base-pair 
monomer units arranged into higher-order arrays throughout the centromere. Nucleosomes that 
replace the canonical histone H3 with the centromeric H3 variant CENPA epigenetically mark the 
centromeric locus. Modern genomics and epigenomics are, however, unable to navigate the highly 
repetitive structure of this region, a technical shortcoming that greatly hinders the ability to study 
their role in human malignancy, which is the second leading cause of death globally. 
Methodologies aimed at characterizing centromeric sequence and function are thus needed to 
effectively study the genetics and molecular biology of the centromere in cancer. Our group has 
developed quantitative PCR assays capable of detecting chromosome-specific α-satellite 
sequences. This novel methodology has enabled us to study centromeres in the contexts of normal 
biology and human disease. 
We demonstrate in this thesis that centromeres undergo both genetic and epigenetic 
alterations in the setting of cancer. Specifically, centromeric α-satellite sequences and 
pericentromeric HERV-K111 retroviral sequences experience copy number reductions and 
sequence homogenization in neoplastic cells and tissue. Furthermore, CENPA, the H3 variant that 
defines centromeric chromatin, was observed to be overexpressed across multiple cancer types, 
with functional significance to prostate cancer phenotypes. Intriguingly, we show that 
overexpressed CENPA possesses a previously uncharacterized function as a putative regulator of 
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gene transcription of important cell cycle, centromere, and kinetochore genes, through ectopic 
localization to their respective transcriptional start sites. 
Our findings collectively underscore the necessity of studying diseases of cell division (i.e. 
cancer) from the perspectives of centromere genetics and epigenetics. Further insight into the 
mechanistic underpinnings of centromere derangements in cancer will provide additional 
molecular context to our understanding of this fundamental structure, thus providing opportunities 
to therapeutically reconfigure centromeres to structurally emulate their normal conformation. 
Repairing the form and function of this structure that is ubiquitously important for cancer 




Chapter 1 – Introduction: Centromeres in Biology and Disease 
 
Cell Division 
Over three centuries have transpired since Robert Hooke first coined the term “cell” in his 
1665 publication Micrographia to describe what we now classify as the fundamental unit of life1. 
Within this historic work, Hooke detailed his use of microscopy to visualize empty spaces 
contained by walls within a thin slice of cork. He called these contained spaces “cells.” This 
discovery galvanized a period of unprecedented study into these building blocks that make up all 
living things2. The variation in structure and function of these microscopic units is now thought to 
underlie the diversity of life-forms on Earth3. This diversity ranges from simple unicellular 
prokaryotes to complex multicellular eukaryotes. Indeed, the complex tissues, organs, organ 
systems and symbiotic unicellular microbiota that govern human biology reflect the importance of 
cellular variation to the maintenance of human life and health4. 
Equally important to human life and health is cellular proliferation, the process by which 
cellular life propagates to facilitate growth and reproduction5. This process is highly conserved 
across all domains of life, where pre-existing cells give rise to new cells through cell division. The 
unifying principle that defines cell division is the segregation of hereditary material from the parent 
cell into each resulting daughter cell. Cell division takes on vastly different forms in prokaryotes 
and eukaryotes, owing to structural differences in their respective hereditary material6. While both 
rely upon chromosomes containing DNA to encode hereditary information, prokaryotes typically 
possess circular chromosomes while eukaryotes possess linear sets of chromosomes. These 
 2 
structural differences necessitate distinct mechanisms to partition chromosomes during cell 
division. Circular chromosomes typically undergo DNA replication and segregation 
simultaneously in a process known as binary fission7. Linear sets of chromosomes, on the contrary, 
require physical and temporal compartmentalization of DNA replication and segregation in order 
to preserve the fidelity of both processes8. The physical and temporal compartmentalization of 
replication and segregation is conferred through the cell cycle, whereby each linear set of DNA is 
replicated first within a membrane bound nucleus and subsequently partitioned by way of either 
meiosis or mitosis8,9. Meiosis is the process by which haploid gametes are produced whereas 
mitosis is the process by which somatic cells produce genetically identical progeny. While their 
products differ genetically and functionally, both result in the partitioning of linear sets of 
chromosomes, thus requiring similar molecular machinery.  
 
Molecular Determinants of Cell Division 
Microscopic evidence of cell division was first published in 1882, when Walther Flemming 
used dyes that selectively bound what were later called chromosomes to depict the segregation of 
threadlike material during various stages of cell division in salamander embryos10. Reconciling 
Flemming’s molecular work with Gregor Mendel’s laws of inheritance ultimately established 
chromosomes as the hereditary material that is transferred from parent to offspring11,12. 
Flemming’s methodology represents one of the first instances by which molecular compatibility 
between a synthetic substance and naturally occurring biological structures (i.e. chromosomes) 
was repurposed for the study of cell biology. Advances in technology have since facilitated 
molecularly driven studies of cell division that demonstrate remarkable specificity. Modern 
renditions of Flemming’s work rely upon compounds that selectively bind molecular targets of 
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interest in order to precisely ascertain spatial and temporal distributions of the molecular 
components essential to cell division13,14. Aided by these techniques, we have uncovered enormous 
complexity within the molecular composition of the cell division machinery. Various structures, 
their subunits, and their derivatives work in a highly coordinated fashion in order to ensure that 
each cell’s set of chromosomes is divided with high fidelity8. 
First, the cell cycle, a process that spatially and temporally separates DNA replication and 
segregation, is orchestrated by molecules termed cyclins and their effector kinases called cyclin-
dependent kinases (CDKs)15. First characterized in 1971 through experimentation with frog 
oocytes, cyclin-CDK complexes (then called the maturation promoting factor) are now known to 
phosphorylate enzymes and structural proteins important for DNA replication, chromosome 
segregation, and cell cycle progression16,17. Cyclins have many isoforms, each of which exhibit 
cell cycle stage dependent abundance. For example, cyclin B and its effector kinase CDK1 together 
initiate and preside over mitosis during M-phase of the cell cycle. Similarly, the G1, S, and G2 
phases of the cell cycle have their own dominant cyclin-CDK complexes5,15,18. 
Second, once the mitotic cyclin-CDK complex has initiated mitosis, a number of structural 
factors are required to physically separate replicated chromosomes (Figure 1.1). Going from distal 
to proximal relative to the chromosomes, centrosomes assemble at opposites poles of the cell 
during prophase, establishing the axis along which cell division will occur19. The centrosomes 
subsequently give rise to the mitotic spindle fibers, composed of the cytoskeletal protein tubulin20. 
Tubulin multimers polymerize towards the chromosomes until they engage multimeric structures 
on each chromosome termed kinetochores21. Kinetochores serve as the molecular interface 
between each chromosome and the spindle fibers tasked with separating replicated strands of 
DNA. Finally, the structural hallmark of chromosomes that specifies the assembly point for the 
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overlying kinetochore is known as the centromere, a genomic locus that is typically situated centric 
to the ends of each chromosome21–23. 
The importance of each of these components to cell division thus suggests that 
derangements in their structure and function are observed in diseases of cell division, i.e. cancer. 
Indeed, numerous components of the molecular machinery for cell division demonstrate altered 
structure and activity in the setting of malignancy24,25. In particular, given the broad consensus 
surrounding genomic instability and epigenetic anomalies in cancer, the centromere presents an 
intriguing focus of study26. Indeed, these genetic loci and their overlying histone profiles serve as 
the nexus for all components of the cell division machinery, given their central positions within 
each chromosome21. Here, I review our current understanding of centromeres and their 
contributions to cancer pathogenesis. 
 
Centromeres 
When Walther Flemming outlined his observations about cell division in 1882, he paid 
particular attention to an area of each chromosome that he called the “primary constriction10.” This 
region, now called the centromere, has since been the subject of much investigation. The 
centromere is an area of specialized chromatin that serves as the foundation upon which the 
kinetochore assembles21–23. The reliance upon centromeres for proper cell division is highly 
conserved across eukaryotic biology27,28. Centromeres have been observed in numerous species, 
with structural differences that guide their respective molecular biology (Figure 1.2). Point 
centromeres are compact loci whose DNA sequences are both necessary and sufficient to specify 
centromere identity and function, as these sequences serve as binding sites for essential 
kinetochore proteins. Regional centromeres are composed of large arrays of repetitive satellite 
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DNA that is often packaged into condensed and largely inaccessible heterochromatin. The DNA 
in regional centromeres contributes to but, does not necessarily define, function28. This variation 
in structure coincides with species variation in genome size and function; point centromeres are 
found in smaller and simpler organisms like budding yeast whereas regional centromeres are found 
in higher order organisms, including humans.   
 
Point Centromeres 
 Point centromeres were first identified in 1980 by Louise Clarke and John Carbon29,30. 
Their finding represents the first time that centromere DNA was isolated for molecular analyses. 
Point centromeres are discreet loci that contain consensus sequences with binding affinity to 
essential kinetochore proteins. In budding yeast (Saccharomyces cerevisiae), where point 
centromeres are best characterized, a single ~125 base pair monomeric sequence is occupied by a 
single nucleosome composed of a histone H3 variant termed Cse4 (Figure 1.2a). Each of the 16 
chromosomes in budding yeast contains the ~125 base pair consensus sequence bound nucleosome 
that subsequently directs the assembly of the kinetochore30. Since this discovery, the field has 
uncovered astounding structural complexity within centromeres across numerous species, 
complexity that serves as the bedrock upon which cell division finds its genesis. The discovery of 
point centromeres led Clarke to subsequently identify regional centromeres in fission yeast 
(Schizosaccharomyces pombe), paving the way for understanding centromeres of higher order 




Regional centromeres are large regions of DNA that serve as the assembly point for the 
kinetochore and the cell division machinery to facilitate separation of chromosomes. Regional 
centromeres are found across eukaryotic species and take on similar structure22,23. The positioning 
of these centromeres relative to the telomeres, or the ends of the chromosomes, produces varied 
chromosomal structures (acrocentric, submetacentric, or metacentric) based on the ratio between 
the length of the q (or long) arm and the p (or short) arm (Table 1.1). The genetic component of 
regional centromeres is defined by highly repetitive DNA sequences arranged in head to tail 
fashion across the entire centromere, where each repeat unit is largely similar but not identical. In 
humans, regional centromeres make up close to 5% of the human genome22. The repetitive 
elements that comprise human centromeres are called a-satellites, which are 171 base pair units 
that are rich in adenine and thymine (Figure 1.2b). Unlike point centromeres, the a-satellite rich 
backbone of regional centromeres is sufficient but not necessary for proper cell division to 
occur23,28. There are a handful of reports that outline the existence of structures termed 
neocentromeres, or centromeres that form in areas of the genome outside of the canonical 
centromere that do not contain a-satellites but that can still recruit the epigenetic factors required 
for cell division32–35. Neocentromeres have been identified in neoplastic settings and are thought 
to be a purely pathologic finding. In the absence of pathology, the epigenetic factors important for 
cell division decorate the a-satellite rich regional centromeres. The factors are components that 
are critical to proper localization and assembly of the kinetochore21. The distinction between the 
genetic and epigenetic components of regional centromeres is thus central to this thesis, as both 
contribute to centromere function in humans and both genomic instability and epigenetic 
anomalies are observed in human cancer. 
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Centromere Genomics: A Wild Frontier 
 While it is widely acknowledged that the a-satellite rich human centromere plays a 
significant role in cell division, large gaps remain in our collective understanding of the precise 
mechanisms by which the human centromere carries out its function22,23. A full end-to-end 
assembly of each human centromere is to this day unavailable, with the exception of the 
centromere from chromosome Y36. These regions thus remain as one of the final uncharted 
frontiers within the human genome. Despite major advancements in next generation sequencing 
(NGS) technology, low-complexity regions characterized by repetitive sequences, including 
centromere a-satellite DNA, have generally been considered refractory to sequencing due to non-
unique alignments that arise during computational assembly of these regions. Bioinformatics 
approaches that require a reference genome for alignment thus traditionally exclude these low-
complexity regions during analysis. 
Recent efforts at overcoming the technical shortcomings of NGS approaches have focused 
on more conventional molecular biology techniques, including extended chromatin fiber analysis, 
fluorescent in-situ hybridization (FISH), and Southern blotting-based approaches22,37–43. 
Chromatin fiber analysis, FISH, and Southern blotting, while effective for qualitatively and 
quantitatively characterizing localization and size of given centromeric proteins and sequences, 
are labor, resource, and time intensive. Polymerase chain-reaction (PCR) based approaches, such 
as those recently developed by Dr. Rafael Contreras-Galindo in our group, offer expedited 
evaluation of the centromeric content within any given sample, making it more scalable than 
chromatin fiber analysis and hybridization-based approaches when evaluating samples derived 
from human cell lines and tissue44. Corroboration of the specificity and sensitivity of PCR-
approaches by a number of orthogonal methodologies, including FISH, Southern blotting, and 
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Sanger sequencing, suggests that using rapid centromere targeted PCR methodologies is a viable 
strategy for studying centromere genetics39,44–46. In this thesis, all genetic interrogation of 
centromeres relies upon PCR-based methodologies, unless otherwise denoted in the data. 
 
Centromere Epigenetics 
 Given the difficulties associated with studying the genetics of human centromeres, efforts 
to study them have focused on the epigenetics that drive centromere assembly (Fig 1.3)47,48. The 
a-satellite sequences that define centromere DNA are primarily occupied by a centromere specific 
histone H3 variant known as CENPA47,49. CENPA is a highly conserved ~17 kDa molecule that 
forms a centromere-specific nucleosome with H2A, H2B and H450. Proper CENPA localization is 
a ubiquitin E3 ligase dependent process, requiring ubiquitination of lysine 124 (K124) for 
engagement with the CENPA specific chaperone HJURP51. HJURP, along with the MIS18 
complex subsequently facilitates the incorporation of newly synthesized CENPA into nucleosomes 
occupying replicated a-satellite DNA52,53. CENPA nucleosomes have a unique set of binding 
partners that facilitate proper genomic localization, including CENPB, CENPC, and the 
constitutive centromere associated network (CCAN) that comprises the inner kinetochore54,55. The 
CCAN serves as a multimeric interface between the DNA-enveloped CENPA nucleosomes and 
the KMN (KNL-1/Mis12 complex/Ndc80 complex) network that comprises the outer kinetochore 
and directly interacts with the microtubule spindle fibers56. CENPA and its associated proteins 
therefore represent structural components that are essential to the integrity of cell division, and 




Cancer: A Disease of Cell Division 
The importance of cell division to human growth and development therefore establishes that 
derangements that occur during the process of cell division can give rise to diseases defined by 
abnormal cell growth and proliferation. Indeed, three of the hallmarks presented in Hanahan and 
Weinberg’s landmark paper in 2000 (and their follow-up paper in 2011) implicate dysregulated 
cell division as a fundamental characteristic that defines cancer26,57. In 2018, there were 17 million 
new cases of cancer worldwide58. Cancer is the second leading cause of death globally, claiming 
9.6 million lives in 2018 according to the World Health Organization (WHO). While the 
underlying reasons are complex, a steadily aging and growing population as well as changes in the 
prevalence and distribution of risk factors are implicated in the rising prevalence and mortality of 
cancer59. Multi-institutional endeavors that catalogue molecular and clinical irregularities within 
cancer tissue in the form of large publicly available databases have provided oncologists and 
cancer biologists a wealth of information to comprehensively interrogate this heterogeneous class 
of diseases60,61. Understanding cancer from the standpoints of cellular and molecular biology is 
imperative to identifying novel therapeutics that can curb the growing burden of disease. 
 
Genomic Instability 
One of the enabling characteristics of cancer outlined by Hanahan and Weinberg in 2011 
is genomic instability and mutation. Of the ten hallmarks, many of them depend upon successive 
genomic alterations to ultimately produce neoplastic cells26. Indeed, many genes that are important 
for regulating the timing and structural definitions of cell division are subjected to mutational 
events that relieve checks on uncontrolled proliferation or produce additional mutations in the form 
of rearrangements or copy number amplification through aneuploidy. These genes include those 
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that encode cyclins, cyclin dependent kinases, and DNA-replication/repair machinery62–66. Certain 
cancers also demonstrate hypermutability phenotypes, owing to mutational loads that accumulate 
due to dysfunctional DNA repair machinery or to chemical carcinogens that increase mutation 
rates in actively dividing cells67–69. Comparative genomic hybridization (CGH) of chromosomes 
from various cancer types has additionally unveiled gross copy number alterations in specific 
genomic loci and sometime of whole chromosomes themselves70. The advent of NGS technologies 
eventually paved the way for The Cancer Genome Atlas (TCGA) Program, a multi-institutional 
effort that has molecularly catalogued over 20,000 primary cancer tissues and matched normal 
samples from 33 cancer types60. Parsing through this massive database has provided high-
resolution assessments of cancer genomes, corroborating much of what we had previously known 
about genomic instability in cancer while simultaneously providing novel insights into biological 




Running parallel to the well-established notion that cancer genomes display widescale 
alterations that confer selective advantage are the discoveries of pathogenic alterations to the 
epigenetic landscape in cancer. Comprehensive evaluation of gene expression, transcription factor 
binding, histone modifications, DNA methylation, and histone variant occupancies have 
uncovered gross alterations in gene regulation and epigenetic function across several cancer 
types71–74. Transcription factors such as c-Myc, FOXM1, and the E2F family, which are important 
for proper timing and initiation of cell division, are almost universally implicated in oncogenic 
gene expression patterns75–81. Polycomb repressor complex 2 (PRC2) component abundance and 
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the resultant increase in the H3K27me3 repressive mark are established markers of disease across 
cancer types82,83. Global DNA hypomethylation is considered a ubiquitous feature of 
carcinogenesis thought to alter gene expression profiles through destabilizing transcriptional 
repression in cancer72,84. Gene regulatory elements that are uncharacteristically occupied by 
promiscuous histone variants, such as H3.3 or macroH2A, have been shown to alter gene 
expression profiles towards those that are reflections of malignant phenotypes85–88. 
 
Derangements in Centromeres 
Genetics 
 Diseases of cell division, particularly cancer, remain largely unexplored within the realm 
of centromere genetics33,89–92. Gaining deeper insight into the contribution of centromere genetics 
to tumorigenesis and cancer progression thus has the potential to inform novel therapeutic 
strategies capable of improving long-term outcomes. Unfortunately, the oncogenic potential of 
centromeric sequences remains undetermined, due to the shortcomings of sequencing 
methodologies. TCGA has largely overlooked these sequences when evaluating loci that are 
frequently altered in cancer, due to the issue of non-unique alignments that arise during 
bioinformatic analyses of sequencing data. However, one can postulate that repetitive loci, which 
are known to undergo recombination events that produce amplifications and deletions, may 
experience expansions and contractions due to the genomic instability that is an enabling feature 
in cancer92–94. Indeed, recombination in centromeres has been observed in maize, resulting in 
sequence evolution with every generation95–97. Chapter 2 of this thesis presents a foray into the 
wild frontier of centromeres in cancer as an effort to gain a better understanding of potentially 
pathological processes that occur within this largely overlooked, but important locus. Using the 
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centromere specific PCR assay developed in-house, we report wide-scale alterations in 
centromeric content in both cancer cell lines and tissue.  
 
Epigenetics 
 Diseases of uncontrolled cell proliferation such as cancer, are compelling to examine from 
the epigenetic perspective of centromere biology. A number of studies have identified aberrant 
expression of centromeric/kinetochore proteins in cancers, where overexpression is predictive of 
survival and response to therapy, though their mechanistic contribution to cancer pathogenesis 
remains elusive24,25,98,99. In the setting of ectopic constitutive overexpression, CENPA, the histone 
H3 variant that epigenetically defines centromeric chromatin, has been shown to bind non-
centromeric DNA. While CENPA localization normally requires engagement with HJRUP 
through a ubiquitin E3 ligase dependent process, CENPA promiscuity for non-centromeric DNA 
in the setting of ectopic overexpression is independent of aberrant E3 ligase activity and reliant 
upon the histone chaperone DAXX100. Ectopic localization of endogenously overexpressed 
CENPA has also been shown in colon cancer cell lines101. CENPA promiscuity thus presents 
another example of altered histone variant occupancy in cancer. The phenotypic consequences of 
such mislocalization in malignancy have yet to be elucidated, though ectopic binding to sites 
marked by DNase hypersensitivity and CTCF transcription factor affinity hint at a potential role 
in regulating gene transcription100,101. In Chapter 3 of this thesis, we aim to expand upon these 
intriguing findings to provide novel insight into the process of ectopic CENPA localization. 
Through the use of cell biology and integrated genomics approaches, we demonstrate a possible 




 Centromeres represent essential structural components to cell division that ensure the 
faithful segregation of chromosomes during mitosis. Through interactions with the overlying 
kinetochore and mitotic spindle fibers, centromeres coordinate the cell division machinery to 
equally partition hereditary material from parent cells to each resulting daughter cell. Centromeres 
are thus compelling to study from both genetic and epigenetic perspectives in diseases of cell 
division such as cancer. Previous work has demonstrated that the epigenetic components of the 
centromere demonstrate uncharacteristic behavior in neoplastic settings, though the functional 
consequences of this behavior have yet to be ascertained. Unfortunately, technologic shortcomings 
limit a more comprehensive characterization of centromere genetics in cancer, and whether genetic 
aberrations may contribute to the promiscuous behavior of the epigenetic factors that define 
centromere chromatin. Novel and integrative methodologies are thus required to gain a more 
complete understanding of how centromeres behave during cancer pathogenesis and progression. 
We here demonstrate large scale genetic alterations in the centromeric locus in cancer cell lines 
and tissue. We further demonstrate that the epigenetic anomalies in centromeric components that 
arise in cancer, such as CENPA overexpression, have functional roles that affect gene regulation 
and transcription, using prostate cancer as our primary disease model. Collectively, this work aims 
to provide clarity to the roles that both the genetics and epigenetics of centromeres play in the 
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Figure 1.1: Schematic depiction of the structural factors necessary for chromosomal 
segregation. Centrosomes produce mitotic spindle fibers that polymerize towards the kinetochore, 
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Figure 1.2: Schematic representation of point and regional centromeres. a) Point centromeres 
in budding yeast contain discreet consensus sequences within centromere DNA elements (CDE I 
– III) that recruit essential kinetochore proteins. The locus is occupied by a single CenH3 histone 
variant called Cse4 (the yeast equivalent of what is called CENPA in humans). b) Regional 
centromeres in humans are large loci composed of 171 base pair a-satellite DNA arranged in a 
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Figure 1.3: Schematic illustration of the epigenetic compartmentalization of the centromeric 
locus in humans and the overlying kinetochore. Most proximal to the DNA on each 
chromosome is the centromeric H3 variant known as CENPA, along with its chaperone, HJURP, 
and recruitment machinery known as the MIS18 complex. The inner kinetochore, also known as 
the constitutive centromere associated network (CCAN), serves as the molecular interface between 






Table 1.1: Centromere position-dependent nomenclature of human chromosomes 
Description Definition Examples 
Telocentric 
Centromere located near the telomere. 
The p-arm is barely visible if visible at 
all. 
No examples in humans. 
Mouse chromosomes are 
characteristically telocentric. 
Acrocentric 
The p-arm of the chromosome is much 
shorter than the q-arm but longer than 
those in telocentric chromosomes. 
Chromosomes 13, 14, 15, 21, 
22, and Y 
Submetacentric The p arm and q arm are similar in length but not equal. 
Chromosomes 2, 4, 5, 6, 7, 8, 
9, 10, 11, 12, 17, 18, X 
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Chapter 2 – The Genomic Landscape of Centromeres in Cancers 
 
Summary 
Centromere genomics remain poorly characterized in cancer, due to technologic limitations 
in sequencing and bioinformatics methodologies that make high-resolution delineation of 
centromeric loci difficult to achieve. We here leverage a highly specific and targeted rapid PCR 
methodology to quantitatively assess the genomic landscape of centromeres in cancer cell lines 
and primary tissue. PCR-based profiling of centromeres revealed widespread heterogeneity of 
centromeric and pericentromeric sequences in cancer cells and tissues as compared to healthy 
counterparts. Quantitative reductions in centromeric core and pericentromeric markers (α-satellite 
units and HERV-K copies) were observed in neoplastic samples as compared to healthy 
counterparts. Subsequent phylogenetic analysis of a pericentromeric endogenous retrovirus 
amplified by PCR revealed possible gene conversion events occurring at numerous 
pericentromeric loci in the setting of malignancy. Our findings collectively represent a more 
comprehensive evaluation of centromere genetics in the setting of malignancy, providing valuable 




The centromere is essential to eukaryotic biology due to its critical role in genome 
inheritance1,2. The nucleic acid sequences that dominate the human centromeric landscape are α-
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satellites, arrays of ~171 base-pair monomeric units arranged into higher-order arrays throughout 
the centromere of each chromosome1–3. These α-satellites underlie a hierarchical network of 
proteins that collectively make up the kinetochore, a large multimeric structure that serves as a 
molecular bridge between chromosomes and microtubule polymers from the mitotic spindle during 
cell division. The interaction between centromeres, kinetochores and microtubule polymers lies at 
the nexus of metaphase and anaphase, ensuring faithful separation of the sister chromatids during 
mitosis.  
 Centromeres are thus critical to maintaining the fidelity of chromosomal segregation in 
proliferating tissues. While much is known about the hierarchical network of proteins that 
epigenetically compartmentalizes centromeres, the genomic foundation of the centromere remains 
largely uncharted. Centromeres remain a genetic black box that encompasses 2-5% of the human 
genome4. Despite advancements in next-generation sequencing (NGS) technologies, full 
assemblies of centromeric loci are still unavailable within the latest builds of the human genome, 
with the exception of a linear assembly of the centromere of chromosome Y5. Low complexity 
genomic regions, characterized by the contiguous arrangement of repetitive sequences, present 
computational challenges owing to nonunique alignments that are impractical for current 
informatics pipelines to navigate. Low complexity regions like centromeric loci are consequently 
excluded from most downstream bioinformatics analyses. 
 Methodologies that can add resolution to the genomic landscape of the centromere will 
thus play an integral role in developing a more nuanced understanding of its contribution to health 
and disease. Efforts to overcome the technical shortcomings of NGS approaches have focused on 
more conventional molecular biology techniques, including extended chromatin fiber analysis, 
fluorescent in-situ hybridization (FISH), Southern blotting, and polymerase chain-reaction (PCR) 
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based approaches4,6–13. While effective for qualitatively and quantitatively characterizing 
localization and size of centromeric proteins and sequences, these methods are labor, resource, and 
time intensive. Diseases of cell division, particularly cancer, remain largely unexplored within the 
realm of centromere genetics, due to the lack of scalable alternatives to sequencing technology14–
18. PCR-based approaches, corroborated for specificity and sensitivity, offer expedited evaluation 
of the centromeric content within any given sample, making it more scalable than chromatin fiber 
analysis and hybridization-based approaches when evaluating samples derived from human cell 
lines and tissue8,9,19,20. Applying scalable PCR-based approaches to the assessment of centromere 
size and structure in biological settings like cancer is therefore critical to contextualizing our 
knowledgebase on centromere genetics. 
 Here we report substantial heterogeneity in the centromeric landscape in cancer cell lines 
and tissues, in terms of copy number differences between tissues as well as differences between 
cancer cells/tissues and healthy cells. Both solid and hematologic tumors demonstrated marked 
copy number alterations in centromeric and pericentromeric repeats, as measured by a previously 
described quantitative centromere-specific PCR assay that targets core centromeric α-satellite 
DNA as well as pericentromeric human endogenous retrovirus (HERV) DNA9. Phylogenetic 
analysis of HERV sequences in several cancer cell lines suggests that pericentromeric sequences 
undergo aberrant recombination during tumorigenesis and/or disease progression, consistent with 
derangements that have been previous reported12,18,21,22. Strikingly, centromeric variation is a 
feature present across cancer tissue types, including primary tissue samples, providing further 
substantiation to the notion that genomic instability in centromeres is a ubiquitous occurrence in 
cancer. Evaluation of the centromeric landscape in the setting of malignancy thus reveals marked 
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genetic alterations that may reflect novel pathophysiologic contributions to the development and 
progression of cancer. 
 
Results 
Cancer Cell Lines Demonstrate Heterogeneous Alterations in Centromeric and Pericentromeric 
DNA 
 NGS approaches to interrogating genetic alterations in cancer have repeatedly 
demonstrated ubiquitous genomic instability that is a hallmark of malignancy. However, the lack 
of an end-to-end assembly of centromeric loci prevents mapping of representative centromeric 
reads to a standardized reference. We have thus employed a rapid PCR-based approach that we 
previously described to evaluate the genomic landscape of centromeres and pericentromeres in 
several human cancer cell lines (Figure 2.1). The method was previously validated by comparison 
to meta-analyses of data from studies using NGS and southern blot, as well as through FISH 
analysis9. The cell lines studied here are representative of a variety of different tissue types, 
originating from both solid and hematologic malignancies. Our PCR-based methodology unveils 
significant heterogeneity in the centromeric and pericentromeric content in all 24 chromosomes 
across tissue types and as compared to healthy cells. This heterogeneity extends to HERVs, such 
as HERV K111, that we have previously shown to reside in pericentromeric regions. Unsupervised 
hierarchical clustering of the chromosome specific repeats demonstrates a striking organization to 
the patterns in centromere heterogeneity, differentiated by the region of the centromere (core or 
pericentromere) to which each repeat localizes. Similar clustering analysis applied across the 
different cell lines revealed that heterogeneity in centromeric and pericentromeric content is tissue 
type agnostic, with the exception of healthy peripheral blood lymphocytes (PBLs) that demonstrate 
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higher relative concordance. The heterogeneity observed reflects a preference for contractions in 
centromeric and pericentromeric content, consistent across numerous tissue types (Figure 2.2 – 
2.6). More specifically, D13Z1, D10Z1, D2Z1, D3Z1, D8Z2, D16Z2, and K111 demonstrated the 
most appreciable losses when collectively assessing all tested cancer cell lines. The nomenclature 
of these α-satellites begins with the letter D, followed by their resident chromosome number (1–
22, X or Y), followed by a Z, and a number indicating the order in which the sequence was 
discovered. Consistent with the global loss of whole chromosomes previously reported in 
teratocarcinoma cells, we noted widescale loss of centromere arrays in teratocarinoma cell lines 
derived from male patients in this study (Figure 2.6)23–26. Of note, K111 deletion stood out as 
ubiquitous across all evaluated cell lines. Collectively comparing normal peripheral blood 
mononuclear cells (PBMCs) to cancer cell lines, grouped by tissue type, revealed marked 
reductions in pericentromeric material, using K111 copy number as a surrogate for pericentromeric 
content (Figure 2.7)12,27. 
 A more focused analysis on breast cancer cell lines allowed us to cross-reference the 
observed heterogeneity in centromeric DNA against known molecular classifications and 
karyotypes for each cell line to ascertain whether centromeric and pericentromeric deletions were 
the result of previously described genetic derangements, such as recurrent molecular alterations or 
whole chromosome copy number loss, as seen in teratocarcinoma cell lines (Figure 2.8)28–33. 
Strikingly, the centromeric content demonstrated heterogeneity across the four molecular subtypes 
for breast cancer (Basal, HER2, Luminal A, and Luminal B); unsurprisingly, healthy PBLs 
clustered together. Similar to other tissue types tested, breast cancer cell lines also demonstrated a 
predilection for contracted centromeres and pericentromeres compared to healthy PBLs (Figure 
2.9). While contraction of D13Z1 in Hs578T, BT474, and MDA-MB-361 can be attributed to loss 
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of whole chromosome 13, contraction of D8Z2 in T47D, D3Z1 and D8Z2 in BT549, and D8Z2 
and D10Z1 in SKBr3 were observed despite well characterized copy number amplifications of the 
respective chromosomes. K111 again demonstrated robust contractions relative to other markers. 
The strong reduction in DYZ3 (α-satellite on chromosome Y) to nearly undetectable levels 
provided validation for the specificity of the rapid PCR-based approach to evaluating centromeric 
content, given the absence of Y-chromosomes in breast cancer cell lines derived from females. 
Taken together, marked heterogeneity in centromeric and pericentromeric DNA is observed in 
cancer cell lines, with a predilection towards contraction when comparing cancer cell lines to 
healthy PBLs. 
 
Gene Conversion of Pericentromeric HERV Sequences in Cancer Cell Lines 
 The genomic landscape of the centromere is characterized by thousands of copies of 
repetitive elements arranged in tandem to form higher order arrays1. Repetitive genomic regions 
are known to be subject to recombination due to sequence homology18,34,35. Intrachromosomal 
recombination is one example of repeat-associated recombination that can lead to either deletions 
that reduce the number of repeat units or gene conversion events that genetically homogenize the 
sequences of repeat units36–38. Interestingly, in contrast to healthy PBLs, we identified drastic 
reductions in pericentromeric K111 sequences across all evaluated cancer cell lines (Figure 2.1 
and 2.8). While real-time PCR demonstrates deletion of centromeric and pericentromeric material 
in cancer cell lines, purely quantitative assessments do not provide insight into other recombination 
events, such as gene conversion. Furthermore, sequence analysis of α-satellites is unreliable for 
identifying gene conversion events. We thus conducted phylogenetic analysis on the sequences of 
real-time PCR amplicons from breast cancer cell lines to identify gene conversion events within 
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K111 loci, given ubiquitous loss of K111 across all cancer cell lines (Figure 2.10a). Our previous 
work has shown that divergence in K111 sequence similarity is dependent on chromosomal 
location of K111 loci12,27. We now show that K111 copies identified in breast cancer cell lines 
demonstrate cell line dependent sequence convergence towards K111 subtypes that organize into 
distinct clades (Figure 2.10b). The K151 cell line (pink) remarkably produced distinct clades that 
emerged in close proximity relative to each other from the same ancestral sequence. Sequences 
amplified from the K151 cell line were notably not distributed heterogeneously throughout the 
tree. Three additional breast cancer cell lines (MDA-MB-435, DT-13, and HCC1599) formed two 
exclusive subtypes that were also separated by phylogenetic analysis. 
 Phylogenetic analysis was also conducted in adult T-cell leukemia (ATL) cell lines and 
revealed similar patterns as in breast cancer (Figure 2.11). ATL26 alone formed three exclusive 
subtypes that diverge in homology from normal K111 clades. Of note, K111 clades arising from 
ATL43 and ATL16 demonstrated strong homology to K111 Solo LTRs, suggesting 
intrachromosomal recombination that has deleted K111, i.e. pericentromeric material. ATL43 and 
ATL16 indeed demonstrate the strongest reductions in K111 copy number relative to other ATL 
cell lines (Figure 2.7). As Solo LTRs are the result of homologous recombination between the 
LTRs flanking endogenous retroviral sequences39–41, ATL cell lines having de novo K111 
sequences with higher relative homology to Solo LTR sequences suggested that pericentromeric 
K111 sequences served as templates for gene conversion. Taken together, cell line dependent 
sequence convergence of HERV-K111 in cancer cell lines suggests that gene conversion events 
are driving sequence evolution within the pericentromeres of cancer cell lines. 
 
Heterogeneous Loss of Centromere DNA in Cancer Tissue 
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 Human cancer cell lines are useful models for evaluating cancer biology and genetics in an 
in vitro setting. Indefinite cellular propagation, however, results in clonal selection for cells that 
have a fitness advantage for growing ex vivo. Such a fitness advantage is sometimes conferred by 
abnormal karyotypes (aneuploidy), a cytogenetic feature that can influence the results of PCR 
based analyses. Cancer tissue itself thus presents the most accurate representation of malignancy-
associated genomic instability that results from microenvironmental pressures that cannot be 
reproduced ex vivo. We thus applied our rapid PCR-based approach to DNA isolated from primary 
cancer tissue. Profiling the centromeric landscape in 9 different ovarian cancer samples against 
matched PBMCs revealed similarly significant loss of a-satellites across multiple chromosomes 
as observed in cell lines (Figure 2.12). Indeed, quantitative assessment of this heterogeneity again 
revealed copy number reductions in the cancer tissue, similar to findings noted in cell lines (Figure 
2.13). Strikingly, a drastic reduction in the centromere of chromosome 17 (D17Z1) was seen in 
ovarian cancer tissue when compared to healthy tissue (Figure 2.13), corroborating previous 
reports of chromosome 17 anomalies in ovarian cancer42. No changes were seen in the single copy 
gene GAPDH found in the arm of chromosome 12. A significant loss in GAPDH is, however, 
noted in Sample 285, raising the possibility that this sample’s karyotype displayed derangements 
that are reflected in the PCR data. Tumor karyotypes for tested samples were, however, unavailable 
for corroboration. 
 While matched blood samples provide reliable non-malignant references to their malignant 
counterparts, comparisons between primary ovarian cancer tissue and matched blood does not 
sufficiently deconvolute tissue specific genetic heterogeneity that may be present in normal 
biologic settings. To expand upon our findings, and to specifically address this latter issue, we 
profiled the centromeres of B-cells and T-cells that were separated by cell-surface marker selection 
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from chronic lymphocytic leukemia (CLL) primary samples. CLL is a malignancy that arises in 
B-cells, as opposed to T-cells, within the bone marrow. Applying our methodology to compare 
patient matched B-cells and T-cells from CLL samples, both cells of lymphocytic lineage, thus 
largely eliminates the confounding contributions of normal development and tissue specificity to 
genetic heterogeneity in the centromere. Fewer repeats per sample were evaluated than in the 
experiments described above due to the limited availability of tumor DNA from each patient. 
Intriguingly, unsupervised hierarchical cluster analysis across patient samples cleanly separates 
healthy cells from diseased cells based on chromosome specific α-satellite abundance (Figure 
2.14). We show contraction of numerous centromeres in malignant CD19+ B-cells as compared to 
their normal CD3+ T-cell counterparts, whereas no changes were seen in the housekeeping gene 
GAPDH found in the arm of chromosome 12 (Figure 2.15). Strikingly, we see no such centromeric 
differences between B-cells and T-cells separated from blood samples derived from healthy 
individuals. Taken together, centromeric contraction is a characteristic that is present in primary 
cancer samples, consistent with our data in cancer cell lines. 
 
Discussion 
 The importance of centromeres to cell division provides a strong rationale for interrogating 
the genetics of the centromere in cancers. The challenges associated with studying the genomic 
landscape of centromeres, owing to the informatics impracticalities of evaluating low complexity 
regions, have however hindered meaningful progress in understanding the contributions of 
centromere genetics to tumorigenesis and cancer progression. Only one previous study reported 
the loss of centromere DNA in leukemia cells using fluorescent in situ hybridization (FISH)43. We 
demonstrate, for the first time, that centromeres and pericentromeres display heterogeneous 
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alterations in the setting of malignancy, both in cancer cell lines and primary samples. We show 
that these heterogeneous alterations reflect marked reductions and gene conversions of repetitive 
elements and HERVs in multiple centromeres and pericentromeres, suggesting that oncogenic 
genomic instability selects against the presence of most centromeric sequences and perhaps for 
certain pericentromeric sequences. While mechanistically uncharacterized, these findings have 
direct implications for our understanding of global genomic instability in cancer, given the 
importance of centromeres to faithful segregation of chromosomes. The loss of centromeric 
material in chromosome 17 described above is an example of the concordance between centromere 
instability and ovarian cancer pathogenesis, given the recurrent alterations in chromosome 17 that 
have been previously described in ovarian cancer42. While in some cases loss of centromeric DNA 
could be attributed to a loss of that entire chromosome, there is also a substantial loss of 
centromeric DNA in specific chromosomes that are known to be euploid or even polyploid in a 
given cancer cell line. Further, we have shown previously that DNA from patients with trisomy 13 
and trisomy 21 exhibit loss of pericentromeric K111 and that DNA from patients with trisomy 21 
exhibit loss of D21Z1, suggesting that pericentromeric and centromeric contraction may drive mis-
segregation of chromosomes 13 and 219. It is thus conceivable that alterations in centromeres and 
pericentromeres may underlie chromosome segregation defects that are routinely observed in the 
context of abnormal cell proliferation. Gaining deeper insight into the mechanism driving gene 
conversion and centromere contraction may facilitate the identification of novel molecular drivers 
that can be targeted to prevent potentially oncogenic mis-segregation events. 
 While the genetics of centromeres in cancer continue to be elucidated, there is a body of 
work that has uncovered dysregulation of centromere epigenetics and transcriptional activity in 
malignancy. Overexpression of CENPA is observed ubiquitously across various cancers, with 
 33 
evidence of ectopic CENPA deposition at extra-centromeric loci across the human genome44–47. 
Satellite RNA abundance is an additional feature that been identified in cell lines and tissue48–50. 
Our findings of genomic contraction of centromeres provides a topographic rationale for the 
redirection of unbound CENPA to readily accessible ectopic loci in the setting of CENPA 
overexpression, though additional work is required to distinguish the role of cancer specific post-
translational modifications in ectopic deposition of CENPA51,52. Moreover, while not 
mechanistically validated, regions that repress transcriptional homeostasis within centromeric loci 
may be lost (but beyond the sensitivity of PCR interrogation) during genomic contraction of 
centromeres and pericentromeres in cancer, thus driving transcriptional activity and 
overexpression of satellite RNAs in malignancy. Indeed, DNA methylation, an epigenetic mark of 
transcriptional repression, is prevalent within centromeric loci53,54. Selective deletion of 
methylated regions in centromeres during cancer pathogenesis may relieve transcriptional 
repression, resulting in overexpression of satellite RNAs. Cancer specific examination of DNA-
methylation at the centromeric region that leverages our PCR methodology will be essential to 
validating this line of reasoning. 
 Instability in centromeric and pericentromeric loci in the setting of malignancy is consistent 
with the global genome instability that is a well characterized hallmark of cancer55. Subsets of 
breast and ovarian cancer have well studied DNA repair aberrations in homologous recombination 
proteins BRCA1/256. Recent genomic profiling of several other malignancies has identified new 
disease subsets classified by molecular alterations in DNA repair genes and pathways57,58. It is 
conceivable that subsets of cancer that are dysfunctional in DNA repair may exhibit pronounced 
heterogeneity in centromeric content. Thus, it must be acknowledged that hypermutability in DNA 
that results from DNA repair dysfunction in cancer may alter centromere and pericentromere 
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sequences enough to prevent detection by PCR, appearing like copy number loss or gene 
conversion in phylogenetic analysis instead of mismatches or single nucleotide polymorphisms 
(SNPs). Stratifying samples by DNA repair signatures prior to profiling the genomic landscape of 
centromeres may provide a strategy for identifying mechanistic contributors to centromere 
contraction in the setting of malignancy. Moreover, genomic profiling of centromeres in cancer 
tissue may produce signatures that are predictive of responders to therapies that target the DNA 
repair machinery, such as poly-ADP ribose polymerase (PARP) inhibitors. 
 In conclusion, we here provide quantitative resolution of the largely uncharacterized 
human centromere in the setting of cancer.  We notably shed light on a region that has been widely 
considered a black box and impervious to rapid and comprehensive inquiry at the genomic level. 
The wide-spread alterations observed in cancer cell lines and primary tissue provide a sound 
rationale to mechanistically interrogate the molecular machinery that is likely driving the selection 
against centromeric material. Mechanistic characterization of genomic instability at centromeric 
loci has the potential to inform therapeutic approaches aimed at improving disease outcomes across 
several cancer types. 
 
Materials and Methods 
Cell Lines and Cell Culture. Cell lines were cultured according to American Type Culture 
Collection (ATCC) recommendations. Cell lines were grown at 37 °C in a 5% CO2 cell culture 
incubator and authenticated by short tandem repeat (STR) profiling for genotype validation at the 




DNA Isolation. DNA extraction was performed on cell lines and tissue with the DNeasy Blood 
and Tissue Kit (QIAGEN) according to manufacturer’s instructions. DNA was preserved at -20° 
C. 
 
Blood and Tumor Cell Separation. Between January 2005 and September 2016 patients with 
chronic lymphocytic leukemia (CLL) evaluated at the University of Michigan Comprehensive 
Cancer Center were enrolled onto this study. The trial was approved by the University of Michigan 
Institutional Review Board (IRB no. HUM00045507). Patients consented for tissue donation in 
accordance with a protocol approved by the University of Michigan’s IRB (IRB no. 
HUM0009149). Written informed consent was obtained from all patients before enrollment in 
accordance with the Declaration of Helsinki. CLL diagnostic criteria were based on the National 
Cancer Institute Working Group Guidelines for CLL. Eligible patients needed to have an absolute 
lymphocytosis (> 5000 mature lymphocytes/μL), and lymphocytes needed to express CD19, 
CD23, sIg (weak), and CD5 in the absence of other pan-T-cell markers. Peripheral blood 
mononuclear cells (PBMCs) were isolated by venipuncture and separated using Histopaque-1077 
(Sigma). Cryopreserved PBMCs (frozen after Ficoll-gradient purification) from CLL blood 
specimens were prepared for FACS and sorted into CD19+ (B-cells) and CD3+ (T-cells) cells as 
previously described60. Ovarian cancer DNA were isolated from Stage IIIc or Stage IV ovarian 
carcinomas. Tumor samples were obtained from the operating room and immediately taken to the 
laboratory for processing. Tissue was maintained in RPMI/10% FBS throughout processing. Fresh 
4 × 4 × 2–mm tumor slices were rinsed several times to remove all loosely attached cells. The 
tissue was then placed in a tissue culture dish and DNA was extracted as described above. 
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Rapid Centromere Target PCR Assay. PCR was conducted on DNA samples from cell lines and 
primary cancer samples according the previously described conditions9. Briefly, copy numbers for 
each centromeric array, proviruses K111/K222, and single-copy genes were measured by qPCR 
using specific primers and PCR conditions as described. PCR amplification products were 
confirmed by sequencing. The qPCR was carried out using the Radiant Green Low-Rox qPCR 
master mix (Alkali Scientific) with an initial enzyme activation step for 10 min at 95°C and 16–
25 cycles consisting of 15 sec of denaturation at 95°C and 30 sec of annealing/extension. 
 
PCR for 5’ and 3’ K111 LTR Insertions. K111 insertions were amplified by PCR using the Expand 
Long Range dNTPack PCR kit (Roche Applied Science, Indianapolis, IN) as described. K111 5’ 
and 3’ LTRs and accompanying flanking regions were amplified. PCR was performed using an 
initial step of 94 °C for 2 min followed by 35 cycles consisting of denaturation at 94 °C for 30 sec, 
annealing at 55 °C for 30 sec, and extension at 68 °C for 5 min. The amplification products were 
cloned into the topo TA vector (Invitrogen, Carlsbad, CA) and sequenced. 
 
Phylogenetic Analysis. Analysis was conducted as outlined previously61. The K111-related LTR 
sequences obtained from the DNA of cell lines, and DNA from human/rodent chromosomal cell 
hybrids were subjected to BLAST analysis against the NCBI nucleotide database. Sequences were 
aligned in BioEdit and exported to the MEGA5 matrix. LTR trees were generated using Bayesian 
inference (MrBayes v 3.262) with four independent chains run for at least 1,000,000 generations 
until sufficient trees were sampled to generate more than 99% credibility. 
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Statistics and Data Analysis. All heatmaps were generated using the gplots, RColorBrewer, and 
plotrix packages within the RStudio integrated development environment for the R statistical 
programming language. Data were log2 normalized to the median values of healthy samples. Tests 
of statistical significance employed two-sided student t-tests, with level of significance denoted on 
appropriate plots. 
 
Data Availability. Sequences of K111-related insertions amplified from human DNA and 
human/rodent somatic chromosomal cell hybrids are deposited in the NCBI database with 
Accession Numbers (JQ790790 - JQ790967). All other data generated or analyzed during this 
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Figure 2.1: Heterogeneous alterations of centromere DNA in cancer cell lines. Heatmap 
representing the abundance of α-satellites specific for each centromere array (rows) obtained by 
qPCR in 50 ng of DNA from healthy cells and from cancer lines (columns). Relative abundance 
is denoted by the gradient legend (top left). Cancer type and α-satellite localization is depicted as 
indicated by the legend (bottom left). Repeats marked with an asterisk (also bolded and italicized) 
represent α-satellites with appreciable alterations across various cell lines relative to healthy 
controls. Data depicting α-satellite abundance are log2 normalized to healthy PBL median values 
(asterisks, red). The nomenclature of these α-satellites begins with the letter D, followed by their 
resident chromosome number (1–22, X or Y), followed by a Z, and a number indicating the order 
in which the sequence was discovered. The DYZ3 repeat was excluded from the analysis to reduce 
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Figure 2.2: Heterogeneous loss of centromeres in acute lymphoblastic leukemia (ALL) cell 
lines. Abundance of centromere specific α-satellites is depicted by the Z-score (Y-axis) of each α-
satellite. The nomenclature of these α-satellites begins with the letter D, followed by their resident 
chromosome number (1–22, X or Y), followed by a Z, and a number indicating the order in which 
the sequence was discovered. The log2 normalized numbers for each α-satellite were normalized 
to the average copy number of a given repeat in DNA from healthy cells (blue circles). Statistical 
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Figure 2.3: Heterogeneous loss of centromeres in cutaneous T-cell lymphoma (CTCL) cell 
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Figure 2.4: Heterogeneous loss of centromeres in B-cell lymphoma (BCL) cell lines. 
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Figure 2.5: Heterogeneous loss of centromeres in melanoma cell lines. Abundance of 
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Figure 2.6: Heterogeneous loss of centromeres in cancer cell lines. Abundance of centromere 
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Figure 2.7: Abundance of pericentromeric K111 across cell lines and PBMCs. Dot plots 
representing the abundance of centromeric HERV env sequences from either PBMCs or cell lines 
with disease type designations listed along the X axis. The gag region of K111 was not assessed 
in our analysis, as select populations and CTCL patients are homozygous null for K111 gag. HIV 
= HIV patient sample, CTCL = Cutaneous T-Cell Lymphoma, BC = Breast Cancer, TCL = T-Cell 
Lymphoma, BCL = B-Cell Lymphoma, ATL = Adult T-Cell Lymphoma. Abundance of K111 is 
depicted by the log2 Z-score (Y-axis). Statistical significance was calculated using a t-test. * = p< 
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Figure 2.8: Genomic profiling of centromeres in breast cancer cell lines. Heatmap representing 
the abundance of α-satellites specific for each centromere array (rows) obtained by qPCR in 50 ng 
of DNA from healthy cells and from breast cancer lines (columns). Relative abundance is denoted 
by the gradient legend (bottom left). Data depicting α-satellite abundance are log2 normalized to 
healthy PBL median values (asterisks). Repeats marked with an asterisk (also bolded and 
italicized) represent α-satellites with appreciable alterations across various cell lines relative to 
healthy controls. Hormone receptor, TP53 status, histologic, and molecular classifications are 
depicted as indicated by the legend (top left). The DYZ3 repeat was excluded from the analysis to 
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Figure 2.9: Heterogeneous loss of centromeres in breast cancer cell lines. Dot plots 
representing the abundance of α-satellites specific for each centromere array (X axis) in breast 
cancer cell lines. Abundance of centromere specific α-satellites is depicted by the Z-score (Y-axis) 
of each α-satellite. The log2 normalized numbers for each α-satellite were normalized to the 
average copy number of a given repeat in DNA from healthy cells (blue circles). Statistical 
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Figure 2.10: Gene conversion of HERV-K111 in breast cancer cell lines. a) Schematic outline 
of the experimental methodology employed to identify gene conversion events. b) Phylogenetic 
analysis conducted on K111 sequences amplified by PCR on breast cancer cell lines (T47D, 
BT549, HCC-1599, MD-MB-435, DT13, DT22, K151, and SKBr3) and human-hamster hybrid 
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cell lines (each containing a single human chromosome) as a reference. Amplicons are labeled and 
color-coded along the edge of the phylogenetic tree according to the cell line that produced the 
amplicon. Amplicons from human-hamster hybrid cell lines are denoted numerically by the human 
chromosome present in each hybrid cell line. Amplicons from K111 5’LTR, 3’LTR, and Solo LTR 
are additionally denoted. An example of gene conversion is shown in the cell line K151, possessing 
clades (pink) that localize in close proximity relative to each other but are not found 
heterogeneously throughout the tree. Convergence on two distinct K111 subtypes can additionally 
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Figure 2.11: Gene conversion of HERV K111 in adult T-cell leukemia (ATL) cell lines. 
Phylogenetic analysis conducted on K111 sequences amplified by PCR in ATL cell lines (ATL26, 
ATL72, ATL16, and ATL43) and heathy cells (brown labels). Amplicons are labeled and color-
coded along the edge of the phylogenetic tree according to the cell line that produced the amplicon. 
Amplicons from human-hamster hybrid cell lines are denoted numerically by the human 
chromosome present in each hybrid cell line. Amplicons from K111 5’LTR and Solo LTR are 
additionally denoted. Recombinant K111 sequences resembling Solo LTRs are seen in cell lines 
ATL43 and ATL16, shown in blue arising from the same ancestral sequence to K111 Solo LTR 
sequences. K111 sequences from heathy PBLs show heterogeneous distribution along the tree and 
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Figure 2.12: Genomic profiling of centromeres in primary ovarian cancer tissue. Heatmap 
representation of rapid PCR data from nine primary ovarian cancer tissue samples with matched 
PBMC DNA. Matched sets from the same patient are grouped by color. PBMC control samples 
and tumor samples are labeled according to the legend (bottom left). Data depicting α-satellite 
abundance are log2 normalized to PBMC median values. Relative abundance is denoted by the 
gradient legend (bottom left). Repeats marked with an asterisk (also bolded and italicized) 
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Figure 2.13: Heterogeneous loss of centromeres in ovarian cancer patients. Dot plots 
representing the abundance of α-satellites specific for each centromere array (X axis) in ovarian 
cancer tumors. Abundance of centromere specific α-satellites is depicted by the log2 Z-score (Y-
axis) of each α-satellite. The log2 normalized numbers for each α-satellite were normalized to the 
average copy number of a given repeat in DNA from healthy cells (blue circles). Statistical 
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Figure 2.14: CLL (malignant B-cells) and patient matched T-cells assessed for select 
centromeric α-satellite markers. Heatmap representation of rapid PCR data from six primary 
CLL and two healthy samples post-separation by indicated cell surface markers into B-cell 
(CD19+) and T-cell (CD3+) populations. Data depicting α-satellite abundance are log2 normalized 
to T-cell median values. Relative abundance is denoted by the gradient legend (bottom left). 
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Figure 2.15: Heterogeneous loss of centromeres in chronic lymphoctyic leukemia (CLL) 
patients. Dot plot representing the abundance of α-satellites specific for each centromere array (X 
axis) in CLL tumors. Abundance of centromere specific α-satellites is depicted by the log2 Z-score 
(Y-axis) of each α-satellite. The log2 normalized numbers for each α-satellite were normalized to 
the average copy number of a given repeat in DNA from healthy cells (blue circles). Statistical 
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Overexpression of centromeric proteins has been identified in a number of human 
malignancies, though their functional and mechanistic contributions to disease progression have 
not been characterized. CENPA, the centromeric histone H3 variant, is the epigenetic mark that 
determines centromere identity. Here, we demonstrate that CENPA is highly overexpressed in 
prostate cancer in both tissue and cell lines, and the level of CENPA expression correlates with 
the stage of disease. Gain-of- and loss-of-function experimentation confirms that CENPA 
promotes prostate cancer cell line growth. Integrated sequencing studies further reveal a previously 
unidentified function of CENPA as a transcriptional regulator that modulates expression of critical 
proliferation, cell-cycle, and centromere/kinetochore genes. Our findings, therefore, suggest a 
previously undescribed biological function for CENPA, a protein normally thought to be solely 
and importantly involved in centromere identity. Identifying a novel function for CENPA as a 
regulator of gene expression represents a major shift in our understanding of the role it plays in 
biology and disease. While CENPA is indeed a crucial factor that epigenetically 
compartmentalizes centromere function during cell division, our findings shed light on a parallel 
mechanism for CENPA that might be involved in perpetuating malignant phenotypes through gene 
regulation. Though this study is focused on interrogating prostate cancer, the scope of these 
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findings might be generalizable to other malignancies and can ultimately serve as a foundation for 
designing therapeutics that selectively target CENPA’s gene-regulatory activity. 
 
Introduction 
 Centromeres are cellular structures that are necessary for the propagation of hereditary 
information1,2. Located centric to the ends of each chromosome, centromeres provide the structural 
foundation for kinetochores, multimeric complexes that serve as molecular interfaces between 
microtubule spindle fibers and individual chromatids during mitosis1. The centromere-
kinetochore-microtubule interaction facilitates separation of the sister chromatids as mitosis 
proceeds from metaphase to anaphase. Centromeres are thus essential to ensuring faithful 
segregation of chromosomes in actively dividing cells. 
 Efforts to study human centromeres have focused on the epigenetics that drive centromere 
assembly3,4. Alpha satellite sequences that define centromere DNA are primarily occupied by the 
centromere-specific histone H3 variant known as CENPA, a highly conserved ~17 kDa molecule 
that forms a centromere-specific nucleosome with H2A, H2B and H43,5,6. The CENPA-specific 
chaperone HJURP facilitates proper localization and incorporation of newly synthesized CENPA 
into nucleosomes occupying replicated alpha satellite DNA through a ubiquitin E3 ligase 
dependent process7–9. CENPA nucleosomes subsequently engage a unique set of binding partners 
that ensure proper genomic localization. These binding partners including CENPB, CENPC, and 
the constitutive centromere associated network (CCAN) that comprises the inner kinetochore10,11. 
The CCAN further serves as a multimeric interface between CENPA nucleosomes and the KMN 
(KNL-1/Mis12 complex/Ndc80 complex) network that comprises the outer kinetochore and 
directly interacts with the microtubule spindle fibers12. 
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 CENPA and its associated proteins therefore represent structural components that are 
essential to the integrity of cell division, and appropriate genomic localization of centromeric 
proteins is consequently a critical event in the cell cycle. Diseases of uncontrolled cell division, 
particularly cancer, are thus compelling to examine from the epigenetic perspective of centromere 
biology, primarily as it pertains to the key epigenetic mark CENPA. A number of studies have 
identified aberrant expression of centromeric/kinetochore proteins in cancers, where 
overexpression is predictive of survival and response to therapy, though their mechanistic 
contribution to cancer pathogenesis remains elusive13–16. In the setting of ectopic constitutive 
overexpression, CENPA mislocalization in HeLa cells is independent of aberrant E3 ligase 
activity, but rather demonstrates a reliance on the histone chaperone DAXX17. Endogenously 
overexpressed CENPA has also been shown to ectopically localize in colon cancer cell lines18. The 
effects of such mislocalization on phenotypes in malignancy have yet to be elucidated, though 
enrichments in ectopic binding to DNase hypersensitivity sites and CTCF transcription factor 
consensus sequences hint at a potential role in regulating gene transcription17,18. 
Here we report that CENPA is highly overexpressed in prostate cancer and that disease 
progression correlates with CENPA expression within a large patient cohort. CENPA knockdown 
markedly decreases proliferation of prostate cancer cells but not that of benign prostate cells, and 
increased expression of CENPA causes benign prostate epithelial cells to proliferate more rapidly. 
Most strikingly, CENPA appears to affect proliferation of prostate cancer cells by acting as a 
transcriptional regulator that modulates expression of genes critical to proliferation, cell cycle 
progression, and centromere/kinetochore integrity. Thus, overexpression of CENPA, a histone 
variant studied in great detail in its role as a centromere epigenetic mark, unexpectedly also 
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Overexpression of Centromeric Factors in Prostate Cancer 
The significance of centromeres to cell division suggests that centromeric components may 
play important roles in development and in diseases of cell division gone awry, particularly in 
cancer. Previous work identified a centromere-kinetochore (CEN-KT) signature that was 
associated with aggressive, treatment-refractory malignancy16. We therefore profiled the 
transcriptomes of different types of malignancies across a compiled catalogue of publicly available 
RNA-sequencing (RNA-seq) databases19. We found that CENPA is ubiquitously overexpressed in 
malignant tissue relative to respective normal counterparts (Figure 3.1A, Table 3.1). These 
observations, combined with the well-characterized contributions of centromeric components like 
CENPA to cell division, suggested conducting a more focused interrogation of these components 
in cancers that display poor prognosis in the context of high proliferation indices. Prostate cancer 
is one such disease, where a high proliferation index is predictive of poor outcomes20,21. New 
treatment strategies are much needed for prostate cancer, which remains the most diagnosed 
malignancy in men and the second leading cause of cancer-related death in men22. While hormonal 
therapy and chemotherapeutic options are available, resistant metastatic disease and life-altering 
side effects, such as urinary incontinence and erectile dysfunction, are everlasting concerns23. In 
view of the above considerations, we performed Sample Set Enrichment Analysis in the prostate 
tissue type cohort containing RNA-seq data from 685 tissue samples19. Gene expression of 
 62 
numerous centromeric components exhibited strong enrichments in prostate cancer tissue relative 
to their normal counterparts (Figure 3.2A, Table 3.2). 
Our analysis corroborates previous reports that characterize some of these components as 
part of the CEN-KT signature that is strongly associated with poor disease outcomes16. We selected 
CENPA from this panel of genes for further assessment, given its central role in centromere 
biology, importance for development, and highly conserved structure, and found a significant 
increase in expression with disease progression (Figure 3.2B)24. This in silico finding was 
validated at the protein level through prostate tissue microarrays stained for CENPA, notably 
demonstrating marked overexpression of CENPA that increased with disease severity (Figure 
3.2C). Importantly, receiver operator characteristic (ROC) analysis of the CENPA-stained prostate 
tissue microarray produced an area under the curve (AUC) of 0.89, orthogonally demonstrating a 
strong association between elevated CENPA expression and metastatic prostate cancer (Figure 
3.1B). Assessment of CENPA expression was also examined in cancer cell line models to 
determine feasibility for more focused molecular inquiry. We verified robust overexpression of 
CENPA in prostate cancer cell lines, as compared to benign prostatic epithelial lines (Figure 
3.2D). The PNT2 benign cell line was a notable exception, likely due to its rapid proliferation rate 
relative to other cell lines we tested (Figure 3.1C). Taken together, CENPA is a well-conserved, 
developmentally important factor abundant in prostate cancer tissue, as seen in a large number of 
patients, and in prostate cancer cell lines, and an increase in its expression at the RNA and protein 
levels is highly correlated with more aggressive disease. 
 
CENPA is Associated with Cell Division in Prostate Cancer 
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The abundance of CENPA in prostate cancer raised the question as to whether 
overexpression plays a functional role in disease pathogenesis and progression. We thus first 
conducted a comparative analysis of CENPA expression relative to the remaining transcriptome in 
prostate cancer to identify associations with biologic concepts that could computationally guide 
functional assessments. Our efforts to profile transcriptomes in human cancer and normal tissue 
facilitates performing transcriptome-wide correlations against nominated genes of interest in a 
tissue specific manner within a large catalogue of samples (n = 10,848). We thus correlated 
CENPA mRNA levels to the expression levels of all other protein coding elements (Table 3.3) to 
deconvolute its relative contribution to prostate cancer progression. CENPA expression tracks 
tightly with a number of previously identified prostate cancer pathogenesis factors including 
CENPF, UBE2C and EZH2 (Figure 3.3A, 3.4C, and 3.4D, Table 3.3). MKI67 (gene encoding 
proliferation marker Ki67) also performed well in our analysis, further suggesting a role for 
CENPA in cellular proliferation (Figure 3.3B). Of note, CENPA does not tightly correlate with 
ACTB (housekeeping gene), AMACR (prostate cancer biomarker), or AR (Figures 3.4A and 3.4B, 
Table 3.3), suggesting a pathogenic process that is independent of androgen signaling, a 
pharmacologically relevant molecular pathway that is frequently targeted in prostate cancer 
treatment. 
Strong associations with cellular proliferation genes and select pathogenesis factors 
independent of AR implicates CENPA as a contributor to a biologic process that is involved in 
androgen refractory prostate cancer progression. In fact, we found that AR signaling actually 
represses CENPA expression in cell culture (Figure 3.5A). We additionally used the Database for 
Annotation, Visualization, and Integrated Discovery (DAVID) to conduct ontology assessments 
on the highest performing genes from our transcriptome-wide correlation against CENPA 
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expression in prostate cancer (r > 0.8)25. Our analysis revealed a correlation between CENPA gene 
expression and biologic concept clusters that highlight centromeres, kinetochores, mitosis, and cell 
division (Figure 3.3C and 3.5B). Concepts that include genes encoding components of the CCAN 
were additionally captured by our analysis. Of note, CDC25C, CDCA5, TOP2A, and CENPU, 
genes known to play roles in cellular proliferation, cell cycle progression and 
centromere/kinetochore integrity, were included in these biological concepts. Pre-ranked Gene Set 
Enrichment Analysis (GSEA) independently confirmed enrichments in gene signatures important 
for cell cycle, cell division, and mitosis (Figure 3.3D and 3.5C). Taken together, CENPA 
expression is strongly linked to gene signatures that underlie processes that govern proliferation, 
cell cycle progression, and centromere/kinetochore integrity in prostate cancer. 
 
CENPA Dependent Proliferation in Prostate Cancer 
 Significant association between CENPA and proliferation signatures is expected given 
the role CENPA plays in the structural integrity of the centromere. There is limited evidence, 
however, concerning CENPA function in human malignancy. We therefore performed loss-of- 
and gain-of-function experiments in cell lines stably expressing either doxycycline-inducible 
short hairpin RNAs against CENPA or EF1A-promoter driven full-length CENPA. Doxycycline 
administration at 2 µg/mL was sufficient to produce robust knockdown of CENPA after 72 hours 
(Figure 3.6A, 3.7A, and 3.7B). CENPA depletion led to a profound growth-inhibitory effect on 
22Rv1, LnCaP, and DU145 prostate cancer cells (Figure 3.6B, 3.6C, 3.6E, 3.7C, and 3.7D). 
CENPA depletion in prostate cancer cells results in an accumulation of cells in G1 that seem to 
be unable to progress through the cell cycle (Figure 3.6D, 3.7E, and 3.7F). Conversely, 
overexpression of CENPA in the 957E-hTERT benign prostate epithelial cell line leads to a 
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profound growth-promoting effect (Figure 3.6F and 3.6G). Interestingly, benign 957E-hTERT 
cells depleted of CENPA do not demonstrate significant proliferative changes, consistent with 
previous reports that cells can proliferate with low levels of CENPA (Figure 3.6G)26. Taken 
together, our data show that CENPA is an essential factor for progression through the cell cycle 
and that overexpression drives proliferation of prostate cancer cells. 
 
Non-Canonical Genomic Localization of CENPA 
 Given prior reports of ectopic deposition in the setting of CENPA overexpression and the 
marked overexpression of CENPA in prostate cancer, we performed native chromatin 
immunoprecipitation followed by sequencing (NChIP-seq) to identify non-centromeric and 
potentially regulatory binding sites for CENPA in prostate cancer. As expected, four a-satellites 
were enriched relative to the IgG control antibodies using a PCR assay we previously devised that 
can distinguish chromosome specific a-satellite DNA from any given centromere, verifying the 
validity of the CENPA ChIP (Figure 3.8A)27. CENPA directed ChIP-seq identified 569 non-
centromeric binding sites in the VCaP prostate cancer cell line within three experimental replicates 
(Figure 3.9A, 3.8C, and 3.8D). One example of such a CENPA binding site is present in the 
promoter region of CDC25C (Figure 3.9B), a cell cycle phosphatase that is critical for progression 
through anaphase that was also identified in our comparative gene expression analysis described 
above (Figure 3.3A). Intriguingly, the promoter of CENPA itself was also bound by CENPA, 
consistent with previously reported results18. CENPA directed ChIP was additionally conducted 
in the benign prostatic epithelial cell line 957E-hTERT to determine whether ectopic CENPA 
binding is a cancer specific observation (Figure 3.8B). CENPA enrichment over the four 
previously assessed a-satellites was significantly lower than that observed in the VCaP cell line, 
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consistent with each cell line’s respective CENPA abundance observed above (Figure 3.2D). 
CENPA directed ChIP-seq for the 957E-hTERT cell line was thus deferred. 
We next conducted a global assessment of CENPA binding sites to obtain a functional 
taxonomy of CENPA-bound genes. Ontologic assessment of genes whose transcriptional start sites 
were in close proximity to CENPA binding sites revealed enrichments in biologic concepts that 
are involved with maintenance of nuclear architecture and organization, such as protein-DNA 
complex assembly (p = 6.44 x 10-18) and chromosome organization (p = 8.70 x 10-13) (Figure 
3.9C). Furthermore, binning CENPA binding sites into categories corresponding to discreet 
locations within the human genome demonstrates a predilection towards binding regulatory 
elements such as promoters and CpG islands (Figure 3.9D). Comparing the number of peaks 
present within any two genomic regions reveals significant overlap between loci considered to be 
regulatory areas (Figure 3.8E). Taken together, we show that CENPA localizes to non-canonical 
genomic loci, with a predilection towards the regulatory elements of genes that control cellular 
proliferation. 
 
Gene Regulation by CENPA 
 Histone variants have been well characterized as modulators of aberrant gene expression 
in cancer. H2A.Z.2, macroH2A, and H3.3 are well documented as key contributors to malignant 
phenotypes in a number of cancer types28–31. CENPA is a centromere specific histone H3 variant 
overexpressed in cancer but whose functional contributions to malignancy have remained elusive. 
CENPA localizing to regulatory elements outside of the centromere near genes involved in 
maintaining nuclear architecture and chromosome organization, however, presents the intriguing 
possibility that CENPA plays a direct and previously unsuspected role in gene regulation. We thus 
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conducted RNA-seq on CENPA-depleted cell lines to evaluate whether removing CENPA 
drastically alters the gene expression profiles of genes bound by CENPA. Doxycycline 
administration at 2 µg/mL was sufficient to produce ~71% (shCENPA1) and ~85% (shCENPA2) 
knockdown of CENPA mRNA relative to the non-targeting control (shNT) after 72 hours (Figure 
3.10A). RNAi off-target effects were excluded by filtering genes that were either differentially 
expressed or dimensionally inconsistent between each independent CENPA-targeted shRNA 
(Figure 3.11A and 3.11B). The remaining 427 differentially expressed genes (DEGs) illustrated 
global transcriptional downregulation in the setting of CENPA depletion (Figure 3.10B and 
3.11C). Indeed, when conducting ontologic assessments on the RNA-seq dataset, we identified 
overlap between concepts bound by CENPA and concepts that are transcriptionally perturbed, 
specifically nuclear architecture and organization (Figure 3.10C). Formal integrative analysis 
between the ChIP-seq and RNA-seq data (obtained from two different prostate cancer cell lines 
for technical reasons) additionally identified a number of genes essential to cellular proliferation 
and centromere/kinetochore integrity that were both bound by CENPA and differentially expressed 
in the setting of CENPA depletion (Figure 3.10D). CDC25C, CDCA5, TOP2A, and CENPU, 
genes whose expression levels were strongly correlated to CENPA expression in prostate cancer 
tissue, were all notably downregulated with CENPA depletion as well as bound by CENPA. Of 
note, cell division was also found to be an additional enriched biologic concept within our RNA-
seq data, again exhibiting similarity with earlier correlative findings in tissue. These findings 
collectively suggest that CENPA is a regulator of transcription for genes important for proliferation 




The centromeric histone H3 variant CENPA is overexpressed in cancer and has the 
propensity to localize to genomic loci that lie outside of the canonical centromere in the setting of 
overexpression. Yet to date, the functional significance of the ectopic localization of CENPA in 
the biological setting of malignancy has been largely unexplored. We demonstrate for the first time 
that CENPA mislocalization has functional consequences through an unexpected role as a 
regulator of gene expression in prostate cancer. CENPA is infrequently mutated and amplified in 
metastatic prostate cancer32,33. Given the relative genomic stability of the CENPA locus, the 
observed phenotypic aberrations that are the result of modulating CENPA expression are likely to 
be epigenetically driven. While histone variants exhibiting aberrant biologic properties in 
malignancy have been studied extensively, previous thought has been that CENPA’s importance 
to cell division and proliferation is purely a function of its role as a structural node for the CCAN 
and KMN network. While its role in the centromere is certainly vital, we now show that ectopic 
deposition of CENPA in prostate cancer likely plays a role in modulating cell division, functioning 
as a regulator of critical proliferation, cell cycle, and centromere/kinetochore genes. These 
observations thus suggest an additional critical way in which this much-studied protein can affect 
cellular proliferation when overexpressed in the setting of cancer. 
Given the ubiquitous nature of CENPA overexpression in cancer, it is conceivable that 
ectopically bound CENPA driving proliferation through transcriptional regulation is a 
generalizable feature exhibited across numerous cancer types. Previous work shows that while 
centromeric/kinetochore proteins are infrequently mutated or amplified in cancer, coordinate 
overexpression of centromeric/kinetochore factors is a common characteristic identified in 
malignancy13. Our findings suggest a potential epigenetic feedforward mechanism by which 
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progressively increasing levels of CENPA drive gene expression of critical proliferation, cell cycle 
progression, and centromere/kinetochore factors that complement shifting mutational landscapes 
previously identified through cancer genomics approaches34. Intriguingly, AR signaling, the most 
commonly targeted and mutated molecular signature in metastatic-castration resistant prostate 
cancer, was not captured by a CENPA focused analysis, a finding that we further confirmed in 
tissue culture experiments. This phenomenon mirrors EZH2 expression changes in response to 
androgen stimulation, implicating CENPA as an additional epigenetic factor that may contribute 
to androgen-refractory progression35. Of note, we observed EZH2 expression indeed tracked 
tightly with CENPA expression in prostate cancer tissue (SI Appendix, Fig. S2D). 
While we show here that prostate cancer tissue and cell lines overexpress CENPA, previous 
work suggests that occupation of only ~4% of the alpha-satellite rich centromere is sufficient for 
producing functional centromeres36. Indeed, benign prostatic epithelial cells do proliferate in spite 
of expressing low levels of CENPA and exhibiting reduced CENPA binding to a-satellite DNA. 
Loss-of-function experimentation yields pronounced growth inhibition in prostate cancer cell lines 
while producing no observable phenotype in a benign prostatic epithelial cell line. Moreover, 
overexpression of CENPA drives proliferation in benign prostatic epithelial cells. These findings 
are consistent with the presence of an ancillary gene regulatory function for CENPA that further 
dictates its control of proliferation in the setting of overexpression and malignancy. Work in HeLa 
cells suggests that overexpressed CENPA is directed to gene regulatory elements through 
interaction with DAXX, a protein that has been previously been shown to be overexpressed in 
prostate cancer37. It is thus conceivable that DAXX carries out a chaperone like function for 
CENPA when they are both overexpressed in prostate cancer, though Re-ChIP assays involving 
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CENPA and DAXX together would be necessary to formally prove the presence of such a 
mechanism. 
 In conclusion, we show here that the much-studied centromeric histone H3 variant CENPA 
likely also has a previously uncharacterized function as an epigenetic regulator of transcriptional 
activity involving genes important for proliferation, cell cycle progression, and centromere and 
kinetochore integrity in prostate cancer. CENPA overexpression, driven by as yet uncharacterized 
oncogenic events, thus potentiates a feedforward loop designed to maintain uncontrolled 
proliferation in cancer. The ubiquitous nature of CENPA overexpression in other malignancies in 
addition to prostate cancer suggests that CENPA-driven gene expression will be present across 
different cancer types, providing a generalizable rationale to exploit CENPA and its downstream 
targets for therapeutic purposes. 
 
Materials and Methods 
Cell Lines and Cell Culture. LnCaP, 22Rv1 and DU145 prostate cancer cell lines were cultured in 
Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal bovine serum 
(FBS) (Atlanta Biologics) and 1% penicillin/streptomycin (P/S), as was the PNT2 prostatic 
epithelial cell line. VCaP and PC3 prostate cancer cell lines were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS and 1% P/S. The RWPE-1 and 957E-
hTERT immortalized prostatic epithelial cell lines were cultured in keratinocyte serum free 
medium (K-SFM) supplemented with 0.05 mg/mL Bovine Pituitary Extract (BPE) and 5 ng/mL 
epidermal growth factor (EGF). All cell lines were grown at 37 °C in a 5% CO2 cell culture 
incubator, authenticated by short tandem repeat (STR) profiling for genotype validation at the 
University of Michigan Sequencing Core and tested for Mycoplasma contamination. 
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Tissue RNA-seq Differential Expression Analysis. Analysis was performed on a compendium of 
10,848 poly(A)+ RNA-sequencing (RNA-seq) libraries containing primary cancer tissue, normal 
tissue, and cancer cell lines from the TCGA, Michigan Center for Translational Pathology, and 
other public sources. Sample Set Enrichment Analysis (SSEA) was performed as previously 
described across all libraries to query CENPA expression in a cancer vs. normal fashion19. Further 
analysis restricted to the prostate tissue type cohort was conducted to determine CENPA 
expression levels at different stages of malignancy. 
 
Ontologic Assessments. CENPA mRNA levels within the cancer cohort were subjected to 
transcriptome-wide correlation studies against all protein-coding genes. All genes satisfying the r 
> 0.8 criteria were included in a custom list for ontologic assessments. This list of genes was ranked 
by the Spearman rho coefficient and subject to pathway analysis. The Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) tool performed ontologic assessments against 
Gene Ontology (GO) terms as well as UniProt concepts. Weighted, pre-ranked Gene Set 
Enrichment Analysis (GSEA) was performed against MSigDB datasets. 
 
Tissue Microarray. CENPA expression in prostatic epithelium was assessed by 
immunohistochemistry (IHC) on a Tissue Microarray (TMA) using a mouse anti-CENPA 
antibody. Benign prostate tissue, high grade prostatic intraepithelial neoplasia (HGPIN), localized 
prostate cancer and metastatic castration resistant prostate cancer (CRPC) tissues were spotted in 
triplicate on the core (n=58 total tissues, n=174 cores). Staining was evaluated by assessing the 
most frequent pattern of intensity at 20x in addition to the percentage of cells showing that pattern. 
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A product score was subsequently calculated (intensity x percentage of cells with the pattern) for 
each core. Receiver operator characteristic (ROC) curve was generated based on average product 
scores. 
 
Quantitative Reverse Transcriptase–Polymerase Chain Reaction (qRT-PCR) Assay. The All Prep 
DNA/RNA Mini Kit (Qiagen) was utilized to isolate RNA from cell lysates. RNase-Free DNase 
(Qiagen) was used to eliminate contaminating genomic DNA. RNA was quantified by the 
NanoDrop 2000 (ThermoFisher Scientific) and diluted to 25 ng/µL. The Step One Plus Real-Time 
PCR System (Applied Biosystems) was utilized for One-Step qRT-PCR reactions and Moloney 
Murine Leukemia Virus Reverse Transcriptase (Promega) for reverse transcription. Gene-specific 
primers were designed and subsequently synthesized by IDT Technologies. A relative 
quantification method was used to analyze qRT-PCR data and subsequently presented as average 
fold change over an internal reference (as internal reference, GAPDH was utilized). All primers 
used for qPCR are detailed in Table 3.4. Three technical replicates were used in each assay, and 
all data shown were from three biological replicates. 
 
Lysates, Antibodies and Immunoblotting. Cells were pelleted, dissolved in 4x Laemmli Buffer, 
sonicated for 30 seconds and immediately placed in ice. Whole cell extracts were then heated for 
an additional two minutes at 95° C and returned to ice. Samples were subsequently separated on 
4-20% SDS-polyacrylamide gels (BioRad) and transferred to polyvinylidene fluoride (PVDF) 
membranes via wet transfer at 80 V for 90 minutes. Membranes were then incubated in blocking 
buffer (phosphate buffered saline, 0.1% Tween, (PBS-T) 5% non-fat dry milk) for an hour at room 
temperature. Primary antibody incubations were conducted with indicated antibodies in blocking 
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buffer at 4° C overnight. Secondary antibody incubations were conducted the following day with 
species appropriate horseradish peroxidase (HRP) conjugated secondary antibodies. Blots were 
developed using enhanced chemiluminescence substrate according to manufacturer’s protocol 
(Millipore). Antibodies against CENPA (Abcam ab13939) and GAPDH (ab181602) were used as 
primary antibodies. 
 
Knockdown and Overexpression Studies. Stable knockdown of CENPA was achieved using the 
pTRIPZ Tet-On system (Dharmacon). Commercial glycerol stocks of bacteria propagating 
plasmids containing two different CENPA-directed shRNAs and a non-targeting shRNA were 
inoculated and cultured for 24 hours. Plasmid DNA was subsequently isolated using the Plasmid 
Maxi Kit (Qiagen) and sent to the University of Michigan Vector Core for lentiviral production. 
22Rv1, DU145, and LnCaP cells were transduced with lentivirus in the presence of 8 µg/mL 
polybrene. After 24 hours, cells were cultured in the presence of 2 µg/mL puromycin. Knockdown 
was achieved through culturing cells with doxycycline at a final concentration 2 µg/mL. 
Doxycycline response was assessed by microscopy, immunoblot, and qRT-PCR. Stable CENPA 
overexpression was achieved using the pLV system driven by an EF1A promoter (VectorBuilder). 
Plasmids and lentivirus were prepared as described for the pTRIPZ system. 957E-hTERT cells 
were incubated with lentivirus in the presence of 8 µg/mL polybrene. After 24 hours, cells were 
cultured in standard K-SFM and subjected to fluorescence-activated cell sorting (FACS) to select 
mCherry positive cells by the University of Michigan Flow Cytometry Core. Overexpression was 




R1881 Treatment. To evaluate the effect of androgen signaling, cells were cultured in medium 
containing 10% charcoal-treated FBS and treated with DMSO vehicle or with 1 nM or 10 nM 
R1881. After 24 and 48 hrs, RNA was isolated and qRT-PCR was performed as described above 
using FastStart SYBR Green Mastermix (Roche). 
 
Cell Proliferation Assays. Cells were seeded in T-25 flasks at 1x106 cells per flask. Flasks were 
evaluated by microscopy 24 hrs following seeding to assess initial confluence. Growth curves were 
constructed by imaging flasks by microscopy, where the growth curves are generated from 
confluence measurements acquired from 6 fields per condition, using the NIS Elements 
microscope imaging software. Proliferation assay was performed for shRNA-mediated 
knockdown, overexpression, and basal growth experiments. 
 
Crystal Violet Assays. Cells were seeded in triplicate in 6-well plates at 1x104 cells per well. Cells 
were given 24 hours to adhere and were subsequently subjected to doxycycline treatments at 2 
µg/mL. Doxycycline was replenished every 2 days to maintain continuity of the pTRIPZ system. 
Treatment was discontinued 7 days after induction. Cells were washed with ice-cold PBS and 
subsequently fixed with methanol. Cells were then stained with 0.5% crystal violet for 10 minutes, 
washed with water, and air-dried. 
 
Cell Cycle Analysis. Cells were subjected to 15 minutes of ethanol fixation at -20° C and 
subsequently collected by centrifugation. Cells were rehydrated at room temperature in PBS, 
pelleted and re-suspended in 3 µM DAPI diluted in staining buffer (100 mM Tris pH 7.4, 150 mM 
NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% Nonidet P-40). Cells were incubated for 15 minutes 
 75 
prior to flow cytometry by University of Michigan Flow Cytometry Core. Cell cycle distribution 
was evaluated using FCS Express. 
 
ChIP-sequencing Library Preparation and Analysis. Native ChIP was conducted as previously 
described38 using a monoclonal antibody against CENPA (Abcam ab13939). CENPA targeted 
ChIP DNA and input control DNA were prepared for parallel sequencing using the TruSeq ChIP 
Library Preparation kit (Illumina) according to the manufacturer’s protocol. Library preparations 
were done in conjunction with the University of Michigan Sequencing Core. Paired-end libraries 
were sequenced with the Illumina HiSeq 4000 (2X150 nucleotide read length) with sequence 
coverage to >50M total reads per sample. FASTQC was employed to assess overall quality of each 
sample followed by TrimGalore processing to trim low-quality bases and adapter sequences. Reads 
were aligned to hg38 using Bowtie2 (version 2.2.1) with default parameters. Principal component 
analysis was conducted to determine the degree of variation between samples. PePr (version 
1.1.14) was employed to identify CENPA bound regions. P-values were adjusted for multiple 
testing using the false-discovery rate (FDR) approach and CENPA bound regions were considered 
significant peaks when p-values < 1.0 x 10-5. Peaks were annotated with annotatr (version 1.0.3). 
Ontology assessments were conducted using ChIP-Enrich39. 
 
RNA-sequencing Library Preparation and Analysis. RNA was isolated as described and RNA 
integrity was evaluated using an Agilent TapeStation. Strand-specific libraries were prepared using 
the TruSeq Stranded mRNA kit (Illumina) according to the manufacturer’s protocol. Library 
preparations were done in conjunction with the University of Michigan Sequencing Core. Paired-
end, strand-specific libraries were sequenced with the Illumina HiSeq 4000 (2X50 nucleotide read 
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length) with sequence coverage to >50 M paired-end reads and >100 M total reads per sample. 
Sequencing results were run through a computational pipeline to trim low-quality bases and 
adapters (TrimGalore), align reads (STAR) to a reference genome (UCSC hg38 from iGenomes), 
quantify gene expression levels (HTseq), and call differentially expressed genes (edgeR). 
Ontology assessments were conducted using RNA-Enrich40. 
 
Data Availability. RNA-sequencing and ChIP-sequencing data are deposited in the MIAME-
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Figure 3.1: Characterization of CENPA in cellular proliferation, and cancer. A) Cancer vs. 
normal analysis conducted across a curated RNA-seq catalogue querying tissue CENPA levels by 
SSEA. B) Receiver operator characteristic (ROC) separating metastatic castration resistant 
prostate cancer (mCRPC) from localized disease by CENPA staining in a tissue microarray. C) 
Proliferation rates of a panel of prostate cancer (LnCaP, VCaP, 22rv1, DU145, and PC3) and 
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Figure 3.2: Overexpression of CENPA in prostate cancer. A) Sample Set Enrichment Analysis 
(SSEA) was used to query a catalogue of curated RNA-seq libraries (n=685) for differentially 
expressed centromeric genes in the prostate tissue type cohort. Genes were selected based on 
associations identified in prior studies with cancer progression and were characterized by their 
inclusion in the previously described CEN/KT signature that negatively impacts therapy response 
and survival. B) Focused SSEA on CENPA mRNA levels in normal prostate (n=52), primary 
prostate cancer (n=501), and metastatic prostate cancer (n=132) tissue. C) Tissue Microarray 
(TMA, n=58 total tissues, n=174 cores) of benign prostate (I), high grade prostatic intraepithelial 
neoplasia (HGPIN), Gleason grade 6-9 prostate cancer, and castration resistant prostate cancer 
(CRPC) (II) tissue stained for CENPA, *P<0.05. Staining was evaluated by assessing the most 
frequent pattern of intensity at 20x and percentage of cells exhibiting that pattern (III). D) 
Immunoblot for CENPA and GAPDH (loading control) in a panel of benign and malignant prostate 
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Figure 3.3: Proliferation signature associated with CENPA. A) CENPA mRNA levels from 
SSEA subjected to a transcriptome-wide correlation. Results were rank-ordered by the strength of 
correlation. Heatmap depicts genes that performed at r ≥ 0.8. B) Scatterplot depicting strong 
concordance between CENPA and the proliferation marker MKI67. C) Top 117 performers from 
transcriptome-wide correlation subjected to functional annotation analysis using the publicly 
available Database for Annotation, Visualization, and Integrated Discovery (DAVID). Enriched 
biological concepts are rank-ordered by their false discovery rate (FDR). D) Independent Gene Set 
Enrichment Analysis (GSEA) of mitotic nuclear division, cell division, and cell cycle gene 
signatures conducted on transcriptome-wide correlation values pre-ranked by the strength of 
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correlation. Barplot depicts enrichment scores from biologic concepts designated along vertical 
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Figure 3.4: Transcriptome-wide correlation against CENPA mRNA levels in prostate cancer. 
A-D) Individual scatterplots depicting correlation strength between CENPA expression, 
previously characterized prostate cancer pathogenesis factors (AMACR, CENPF, and EZH2) and 
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Figure 3.5: Association between CENPA mRNA levels and cell division in prostate cancer. 
A) VCaP prostate cancer cell lines treated with the androgen agonist R1881 and evaluated for 
CENPA and TMPRSS2 (androgen-responsive positive control) expression by qRT-PCR. *P<0.05, 
**P<0.01, comparing to DMSO for each condition and time point via Student's t-test.  B) 
Additional biological concepts identified as associated with CENPA expression through functional 
annotation analysis using DAVID, highlighting enrichments in concepts important for centromeric 
and kinetochore integrity. C) Representative enrichment plots from GSEA of “Cell Division” (left) 
and “Mitotic Nuclear Division” (right) gene signatures conducted on transcriptome-wide 
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Figure 3.6: Functional importance of CENPA in prostate cancer cells. A) Immunoblot for 
CENPA and GAPDH in 22Rv1 cells expressing a doxycycline inducible vector encoding a non-
targeted and two independent CENPA-targeted shRNAs. B) Growth curve depicting proliferation 
over 7 days following doxycycline induction in CENPA knockdown cell lines. Error bars represent 
the standard error of three biologic replicates. *P<0.05, **P<0.01, comparing to shNT for each 
condition via Student's t-test. C) Crystal violet cell proliferation assay conducted 7 days post-
doxycycline induction. D) Cell cycle analysis with DAPI in CENPA shRNA-depleted cells 
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compared to shNT. E) Quantification of crystal violet colonies in panel C. Error bars represent the 
s.e.m. of three biologic replicates. F) Immunoblot for CENPA and GAPDH in 957E-hTERT 
benign prostatic epithelial cells expressing a vector encoding a constitutively active CENPA 
construct (CENPA-OE). G) Growth curve depicting proliferation over 7 days following CENPA 
overexpression or knockdown in 957E-hTERT cells. Error bars represent the standard error of 
three biologic replicates. *P<0.05, **P<0.01, ***P<0.001, comparing CENPA-OE to ORF_91bp 
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Figure 3.7: Panel of prostate cancer cell lines subjected to CENPA depletion. A, B) 
Immunoblot for CENPA and GAPDH in LnCaP and DU145 cells expressing a doxycycline 
inducible vector encoding a non-targeted and two independent CENPA-targeted shRNAs. C, D) 
Growth curve depicting proliferation over 7 days following doxycycline induction in CENPA 
knockdown cell lines (left – LnCaP, right – DU145). Error bars represent the standard error of 
three biologic replicates. *P<0.05, **P<0.01, comparing to shNT for each condition via Student's 
t-test. E, F) Cell cycle analysis with DAPI in CENPA shRNA-depleted LnCaP and DU145 cells 
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Figure 3.8: CENPA N-ChIP-seq validation. A) Validation of native chromatin 
immunoprecipitation (N-ChIP) efficiency of CENPA, through PCR targeting individual 
centromeric repeats. B) N-ChIP-PCR conducted in benign prostatic epithelial cell line 957E-
hTERT. C) Principal Component Analysis (PCA) to determine variation in N-ChIP-seq replicates. 
D) Heatmap depicting correlation strength between each individual N-ChIP-seq sample. Bottom 
left and top right indicate near perfect consistency between ChIP and input replicates, further 
validated by the unsupervised hierarchical clustering (see dendrogram along the vertical 
component). E) Matrix depicting the degree of overlap of CENPA occupancy between different 
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Figure 3.9: Deposition of CENPA at regulatory regions across the genome in prostate cancer 
cells. A) Heatmap across 4 kb windows of CENPA ChIP vs. input signals centered at the CENPA 
peaks. B) UCSC Genome Browser illustration of CENPA binding to transcriptional start site (TSS) 
of the CDC25C gene on chromosome 5. C) 569 CENPA peaks were subjected to Gene Ontology 
assessment. Representative concepts are rank ordered by their FDR. D) CENPA peaks were 
annotated against 16 genomic regions relative to known genes. Abbreviations: CDS – coding 
sequence, UTR – untranslated region, CGI – CpG Island. Peak abundance (black bars) was 
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Figure 3.10: Transcriptional profile of CENPA depleted prostate cancer cells. A) Jitterplot 
reflecting CENPA knockdown efficacy across all replicates. B) Heatmap representation of the 427 
differentially expressed genes (DEGs) when comparing a non-targeting shRNA to two 
independent CENPA targeted shRNAs. Unsupervised hierarchical clustering was performed to 
group samples (columns) and genes (rows) by similarities in data structure. C) Ontologic 
assessments conducted on the 427 DEGs using the RNAEnrich program. A subset of significant 
concepts from the analysis of CENPA depleted cells are depicted. KEGG and GO are databases 
that reflect ontologies representative of connected biologic processes. D) Transcriptional profile 
of CENPA depleted 22Rv1 cells merged with CENPA ChIP-seq data from VCaP. Genes listed 
demonstrate both differential expression with CENPA depletion as well as CENPA binding. 
Directionality of differential expression for each gene is depicted in the right column. Only genes 
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Figure 3.11: CENPA-depletion RNA-seq quality control. A) Scatterplot comparing the 
directionality of differentially expressed genes from the two independent CENPA-targeted 
shRNAs. B) Volcano plot depicting significance against fold change (FC) between shNT and two 
independent CENPA-targeted shRNAs. Genes that satisfied the absolute FC > 1.5 (blue lines) and 
p-value < 0.01 (top right and top left) criteria were considered differentially expressed. C) Venn 
diagrams illustrating the overlap in differential gene expression by comparison of analysis pairs 





Table 3.1: Cancer vs. normal sample set enrichment analysis performed across tissue types 
for tissue CENPA expression. 
*CH: Chromophobe Renal Cell Carcinoma; GBM: Glioblastoma multiforme 
Tissue Type Enrichment Score (ES) Normalized ES (NES) FDR Percentile 
Uterus: Endometrial 0.82400674 4.45339332 <<<0.00001 0.993245958 
Prostate 0.62010533 4.7605022 <<<0.00001 0.986821833 
Kidney: CH* 0.5436092 2.61474901 0.001257495 0.882046881 
Colon 0.82709628 5.88013794 <<<0.00001 0.982360294 
Bladder 0.75358915 3.98232218 <<<0.00001 0.994756839 
Thyroid 0.27684852 2.61333875 0.000382503 0.654878626 
Lung: Squamous 0.98630798 7.85019046 <<<0.00001 0.999219786 
Esophagus 0.86499405 3.59421046 <<<0.00001 0.997247915 
Head/Neck 0.82944953 6.20450438 <<<0.00001 0.998761127 
Stomach 0.76970363 5.34637779 <<<0.00001 0.991716617 
Breast 0.79628032 9.41603282 <<<0.00001 0.996246823 
Rectum 0.68856615 2.52076371 0.002767945 0.90579198 
Kidney: Renal Cell 0.75847375 6.87649952 <<<0.00001 0.975200584 
Cholangiocarcinoma 1 3.38185023 <<<0.00001 0.867112947 
Kidney: Renal Papillary 0.75839376 4.50619268 <<<0.00001 0.983743856 
Lung: Adenocarcinoma 0.86407524 7.14574446 <<<0.00001 0.992993828 
Liver 0.90532684 6.72891874 <<<0.00001 0.994865907 




Table 3.2: Sample set enrichment analyses comparing expression levels of centromere and 
kinetochore genes in normal prostate tissues, primary prostate cancers, and metastatic 
prostate cancers. 





ENSG00000115163.13 Metastasis vs. Primary 0.677312 7.644799 <<<0.00001 0.982245411 
ENSG00000115163.13 Metastasis vs. Normal 0.831278 5.604697 <<<0.00001 0.983979735 
ENSG00000115163.13 Cancer vs. Normal 0.620105 4.760502 <<<0.00001 0.986821833 
ENSG00000129810.13 Metastasis vs. Primary 0.733815 8.111382 <<<0.00001 0.988213656 
ENSG00000129810.13 Metastasis vs. Normal 0.854931 5.903665 <<<0.00001 0.989456749 
ENSG00000129810.13 Cancer vs. Normal 0.474081 3.714663 4.43E-07 0.946241884 
ENSG00000117724.11 Metastasis vs. Primary 0.674255 7.850147 <<<0.00001 0.984572651 
ENSG00000117724.11 Metastasis vs. Normal 0.832376 5.956698 <<<0.00001 0.990244069 
ENSG00000117724.11 Cancer vs. Normal 0.551631 4.368803 <<<0.00001 0.976147243 
ENSG00000123485.10 Metastasis vs. Primary 0.652578 7.61156 <<<0.00001 0.98187005 
ENSG00000123485.10 Metastasis vs. Normal 0.844991 5.728154 <<<0.00001 0.986033615 
ENSG00000123485.10 Cancer vs. Normal 0.643455 5.051252 <<<0.00001 0.992104105 
ENSG00000138778.10 Metastasis vs. Primary 0.7042 8.101394 <<<0.00001 0.988025975 
ENSG00000138778.10 Metastasis vs. Normal 0.874649 6.131515 <<<0.00001 0.993256427 
ENSG00000138778.10 Cancer vs. Normal 0.450099 3.641762 4.43E-07 0.941152195 
ENSG00000151725.10 Metastasis vs. Primary 0.605186 7.05999 <<<0.00001 0.974775722 
ENSG00000151725.10 Metastasis vs. Normal 0.80322 5.746591 <<<0.00001 0.986581317 
ENSG00000151725.10 Cancer vs. Normal 0.468724 3.758717 4.43E-07 0.948470342 
ENSG00000102384.12 Metastasis vs. Primary 0.682269 7.739223 <<<0.00001 0.983446567 
ENSG00000102384.12 Metastasis vs. Normal 0.848675 5.837062 <<<0.00001 0.988053264 
ENSG00000102384.12 Cancer vs. Normal 0.308641 2.41594 0.003485 0.828656322 
ENSG00000123219.11 Metastasis vs. Primary 0.654545 7.487768 <<<0.00001 0.980593822 
ENSG00000123219.11 Metastasis vs. Normal 0.758751 5.215585 <<<0.00001 0.974531886 




Table 3.3: Transcriptome-wide correlation results against CENPA expression in prostate 
cancer tissue samples (n=633) rank ordered by correlation strength. Table restricted to genes 
with r > 0.8. 
Gene ID Gene Name Gene Type Coefficient p-value 
ENSG00000115163.13 CENPA protein_coding 1 0 
ENSG00000088325.14 TPX2 protein_coding 0.953247713 0 
ENSG00000175063.15 UBE2C protein_coding 0.949233385 0 
ENSG00000100526.18 CDKN3 protein_coding 0.942322286 3.90E-302 
ENSG00000117399.12 CDC20 protein_coding 0.940619244 2.88E-298 
ENSG00000117650.11 NEK2 protein_coding 0.940405145 8.65E-298 
ENSG00000090889.11 KIF4A protein_coding 0.939524776 7.66E-296 
ENSG00000126787.11 DLGAP5 protein_coding 0.939319726 2.16E-295 
ENSG00000089685.13 BIRC5 protein_coding 0.938308668 3.36E-293 
ENSG00000075218.17 GTSE1 protein_coding 0.936094029 1.60E-288 
ENSG00000137804.11 NUSAP1 protein_coding 0.933599848 1.88E-283 
ENSG00000143228.11 NUF2 protein_coding 0.932731673 9.85E-282 
ENSG00000112984.10 KIF20A protein_coding 0.931277019 6.64E-279 
ENSG00000170312.14 CDK1 protein_coding 0.929232336 4.96E-275 
ENSG00000158402.17 CDC25C protein_coding 0.928026105 8.43E-273 
ENSG00000138180.14 CEP55 protein_coding 0.927882891 1.54E-272 
ENSG00000165304.6 MELK protein_coding 0.926369475 8.45E-270 
ENSG00000109805.8 NCAPG protein_coding 0.922418309 6.45E-263 
ENSG00000169679.13 BUB1 protein_coding 0.92241255 6.60E-263 
ENSG00000165480.14 SKA3 protein_coding 0.922179349 1.64E-262 
ENSG00000135451.11 TROAP protein_coding 0.919163683 1.62E-257 
ENSG00000121152.8 NCAPH protein_coding 0.916186482 9.00E-253 
ENSG00000087586.16 AURKA protein_coding 0.916174417 9.40E-253 
ENSG00000186185.12 KIF18B protein_coding 0.916080692 1.32E-252 
ENSG00000146670.8 CDCA5 protein_coding 0.915046688 5.30E-251 
ENSG00000142945.11 KIF2C protein_coding 0.914678507 1.95E-250 
ENSG00000072571.18 HMMR protein_coding 0.914549332 3.08E-250 
ENSG00000105011.7 ASF1B protein_coding 0.91427943 7.97E-250 
ENSG00000171848.12 RRM2 protein_coding 0.913730469 5.46E-249 
ENSG00000237649.6 KIFC1 protein_coding 0.912124451 1.41E-246 
ENSG00000129810.13 SGOL1 protein_coding 0.911795314 4.36E-246 
ENSG00000117724.11 CENPF protein_coding 0.911751692 5.06E-246 
ENSG00000169607.11 CKAP2L protein_coding 0.910515383 3.33E-244 
ENSG00000131747.13 TOP2A protein_coding 0.910413271 4.69E-244 
ENSG00000101057.14 MYBL2 protein_coding 0.908588507 2.01E-241 
ENSG00000152253.7 SPC25 protein_coding 0.908524197 2.49E-241 
ENSG00000145386.8 CCNA2 protein_coding 0.907887864 2.00E-240 
ENSG00000109674.3 NEIL3 protein_coding 0.90739416 9.94E-240 
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ENSG00000166851.13 PLK1 protein_coding 0.907201273 1.86E-239 
ENSG00000123485.10 HJURP protein_coding 0.90714193 2.25E-239 
ENSG00000183856.9 IQGAP3 protein_coding 0.90557122 3.45E-237 
ENSG00000111665.10 CDCA3 protein_coding 0.901495447 1.09E-231 
ENSG00000111206.11 FOXM1 protein_coding 0.901026443 4.51E-231 
ENSG00000164611.11 PTTG1 protein_coding 0.900555263 1.87E-230 
ENSG00000011426.9 ANLN protein_coding 0.89990179 1.32E-229 
ENSG00000135476.10 ESPL1 protein_coding 0.89973951 2.15E-229 
ENSG00000154839.8 SKA1 protein_coding 0.899334885 7.16E-229 
ENSG00000076382.15 SPAG5 protein_coding 0.897243566 3.33E-226 
ENSG00000134690.9 CDCA8 protein_coding 0.897162757 4.21E-226 
ENSG00000171241.7 SHCBP1 protein_coding 0.895676201 3.05E-224 
ENSG00000066279.15 ASPM protein_coding 0.894498322 8.66E-223 
ENSG00000035499.11 DEPDC1B protein_coding 0.894092574 2.72E-222 
ENSG00000013810.17 TACC3 protein_coding 0.893768311 6.76E-222 
ENSG00000137807.12 KIF23 protein_coding 0.89050008 5.58E-218 
ENSG00000178999.11 AURKB protein_coding 0.889938345 2.56E-217 
ENSG00000077152.8 UBE2T protein_coding 0.887617124 1.26E-214 
ENSG00000174371.15 EXO1 protein_coding 0.887581464 1.38E-214 
ENSG00000051341.12 POLQ protein_coding 0.887002447 6.36E-214 
ENSG00000104147.7 OIP5 protein_coding 0.886376225 3.28E-213 
ENSG00000118193.10 KIF14 protein_coding 0.88611361 6.50E-213 
ENSG00000168078.8 PBK protein_coding 0.885390953 4.24E-212 
ENSG00000065328.15 MCM10 protein_coding 0.88287278 2.65E-209 
ENSG00000198901.12 PRC1 protein_coding 0.876931157 5.93E-203 
ENSG00000163808.15 KIF15 protein_coding 0.876690103 1.06E-202 
ENSG00000068489.11 PRR11 protein_coding 0.875783463 9.16E-202 
ENSG00000161888.10 SPC24 protein_coding 0.874162081 4.18E-200 
ENSG00000121211.6 MND1 protein_coding 0.873879568 8.09E-200 
ENSG00000138778.10 CENPE protein_coding 0.873655133 1.37E-199 
ENSG00000085999.10 RAD54L protein_coding 0.87323259 3.65E-199 
ENSG00000129195.14 FAM64A protein_coding 0.873200215 3.93E-199 
ENSG00000127564.15 PKMYT1 protein_coding 0.870136858 4.39E-196 
ENSG00000137812.18 CASC5 protein_coding 0.869693748 1.19E-195 
ENSG00000276043.3 UHRF1 protein_coding 0.8690451 5.13E-195 
ENSG00000091651.7 ORC6 protein_coding 0.868969543 6.08E-195 
ENSG00000148773.11 MKI67 protein_coding 0.867715775 9.94E-194 
ENSG00000151725.10 CENPU protein_coding 0.867167902 3.34E-193 
ENSG00000156970.11 BUB1B protein_coding 0.865106175 3.05E-191 
ENSG00000007968.6 E2F2 protein_coding 0.864803155 5.88E-191 
ENSG00000093009.8 CDC45 protein_coding 0.864549042 1.02E-190 
ENSG00000184661.12 CDCA2 protein_coding 0.861725496 4.25E-188 
ENSG00000102384.12 CENPI protein_coding 0.8615679 5.93E-188 
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ENSG00000198826.9 ARHGAP11A protein_coding 0.858654441 2.59E-185 
ENSG00000143476.16 DTL protein_coding 0.858074052 8.57E-185 
ENSG00000167900.10 TK1 protein_coding 0.85737153 3.61E-184 
ENSG00000138160.5 KIF11 protein_coding 0.85714429 5.75E-184 
ENSG00000166803.9 KIAA0101 protein_coding 0.855859296 7.80E-183 
ENSG00000139734.16 DIAPH3 protein_coding 0.855388765 2.02E-182 
ENSG00000186871.6 ERCC6L protein_coding 0.853544067 8.05E-181 
ENSG00000161800.11 RACGAP1 protein_coding 0.851907563 2.03E-179 
ENSG00000146410.10 MTFR2 protein_coding 0.85137979 5.71E-179 
ENSG00000154920.13 EME1 protein_coding 0.848101678 3.20E-176 
ENSG00000113368.10 LMNB1 protein_coding 0.841708517 4.81E-171 
ENSG00000188610.11 FAM72B protein_coding 0.841587693 6.00E-171 
ENSG00000157456.6 CCNB2 protein_coding 0.836448844 5.92E-167 
ENSG00000122966.12 CIT protein_coding 0.835824278 1.77E-166 
ENSG00000101412.12 E2F1 protein_coding 0.835231932 4.98E-166 
ENSG00000071539.12 TRIP13 protein_coding 0.83289595 2.84E-164 
ENSG00000106462.9 EZH2 protein_coding 0.832630908 4.47E-164 
ENSG00000134057.13 CCNB1 protein_coding 0.83135339 3.96E-163 
ENSG00000171320.13 ESCO2 protein_coding 0.826995672 5.88E-160 
ENSG00000094804.8 CDC6 protein_coding 0.825740153 4.64E-159 
ENSG00000167513.7 CDT1 protein_coding 0.824746176 2.35E-158 
ENSG00000075702.15 WDR62 protein_coding 0.823395844 2.10E-157 
ENSG00000121621.6 KIF18A protein_coding 0.821762945 2.90E-156 
ENSG00000196550.9 FAM72A protein_coding 0.820033411 4.53E-155 
ENSG00000197299.9 BLM protein_coding 0.819740648 7.19E-155 
ENSG00000117632.19 STMN1 protein_coding 0.819190897 1.71E-154 
ENSG00000129173.11 E2F8 protein_coding 0.818021052 1.07E-153 
ENSG00000165490.11 DDIAS protein_coding 0.817674061 1.84E-153 
ENSG00000101003.9 GINS1 protein_coding 0.815175278 8.75E-152 
ENSG00000123219.11 CENPK protein_coding 0.815104073 9.75E-152 
ENSG00000185480.10 PARPBP protein_coding 0.815102512 9.78E-152 
ENSG00000164087.6 POC1A protein_coding 0.811596424 2.00E-149 
ENSG00000085840.11 ORC1 protein_coding 0.810709703 7.55E-149 
ENSG00000278023.3 RDM1 protein_coding 0.80986939 2.64E-148 
ENSG00000165244.6 ZNF367 protein_coding 0.807180403 1.39E-146 
ENSG00000139354.9 GAS2L3 protein_coding 0.802631464 9.90E-144 




Table 3.4: Primers used in this chapter. 
Direction Target Method Sequence 
GAPDH F GAPDH qRT-PCR ACATCGCTCAGACACCATG 
GAPDH R GAPDH qRT-PCR TGTAGTTGAGGTCAATGAAGGG 
CENPA F CENPA qRT-PCR GTGTGGACTTCAATTGGCAAG 
CENPA R CENPA qRT-PCR TGCACATCCTTTGGGAAGAG 
TMPRSS2 F TMPRSS2 qRT-PCR CCTGCAGGGACATGGGCTATA 
TMPRSS2 R TMPRSS2 qRT-PCR CCGGCACTTGTGTTCAGTTTC 
D2Z1 F D2Z1 ChIP-PCR TCGTTGGAAACGGGATTGT 
D2Z1 R D2Z1 ChIP-PCR CTGCTCTATGAAAGGGACTGTT 
D11Z1 F D11Z1 ChIP-PCR CTTCCTTCGAAACGGGTATATCT 
D11Z1 R D11Z1 ChIP-PCR GCTCCATCAGCAGGATTGT 
DXZ1 F DXZ1 ChIP-PCR CGGGATCACCTTCCCATAAC 
DXZ1 R DXZ1 ChIP-PCR GGTGTTGCAAACCTGAACTATC 
D20Z2 F D20Z2 ChIP-PCR TGCTTGGAAACGGGAATGT 
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Chapter 4 – Conclusion: Future Directions for Studying Centromeres 
 
Summary of Dissertation 
  The aim of the work encapsulated in this thesis was to ascertain the role centromeres play 
in cancer. The well-established contributions of centromeres to faithfully orchestrating 
chromosomal segregation, as well as some early data in the literature, bestow biologic rationale to 
further interrogate this essential subcellular structure in the context of malignancy. The findings 
presented here reflect the degree to which alterations in centromere genetics and epigenetics have 
been overlooked in our quest towards a more complete understanding of the molecular 
determinants of cancer. Two immediate future directions can be readily surmised from this thesis 
work: 1) instability in centromeric loci requires further elucidation to mechanistically delineate 
factors that drive the aberrations observed in the genomic centromere; and 2) epigenetic 
promiscuity exhibited by CENPA in prostate cancer may be generalizable across additional 
centromeric factors as well as across additional cancer tissue lineages. 
 
Genomic Derangements 
Global genome instability in cancer underscored our supposition that centromere DNA 
undergoes molecular alterations that have gone unnoticed due to technologic shortcomings in NGS 
methodologies that hinder interrogation of repetitive loci1. The repetitive landscape of the genomic 
centromere thus necessitated that we use a methodology that can successfully navigate low-
complexity regions of the human genome. Previous work had characterized a novel PCR-based 
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methodology that takes advantage of the rare divergences in homology between chromosome 
specific a-satellites to quantify copy numbers of chromosome specific repeat units2. The 
specificity of this assay lends itself to applications that seek to characterize centromeric genetics 
through copy number assessments of the a-satellites that reside within each chromosome. Prior 
reports in a number of model organisms described copy number alterations at centromeric loci due 
to recombination and retrotransposition of centromeric DNA, motivating us to apply this PCR 
methodology to study potential a-satellite copy number alterations in cancer3–10. We thus began 
by applying this methodology to DNA samples from cancer cell lines, tissues, and normal controls, 
hypothesizing that our assay would unveil cancer-associated copy number variation in centromeric 
DNA. 
 The ease of use of our centromere-specific PCR assay allowed us to broadly examine the 
genetic landscape of centromeres across numerous cancer types. We found heterogeneous losses 
in centromeric material in terms of copy number differences between tissues as well as differences 
between cancer cells/tissues and healthy cells in a manner independent of aneuploid karyotypes.  
The heterogeneous copy number losses identified in centromeric DNA from cancer cell lines was 
also identified in both bulk cancer tissue and flow sorted cancer tissue. Within a particular locus, 
we identified evolution in the sequences of the HERV-K111 virus in the form of gene conversion 
events that homogenized HERV-K111 sequence relative to K111 copies evaluated within normal 
cells. Taken together, we confirm our hypothesis that gross derangements in centromeric DNA in 
the form of copy number alterations and gene conversion is nearly ubiquitous within cancer. Our 
novel PCR assay provides insight into a genetic locus that has been widely-deemed as impervious 
to genomic inquiry. These findings thus shed light on a largely overlooked region of the human 




 Numerous reports in the literature have however deemed a-satellite DNA as sufficient but 
not necessary for centromere function11–14. The field widely accepts that human centromere 
function is defined not just by its genetic underpinnings, but also by its epigenetic composition. It 
thus follows that these postulates must inform our interrogation of centromeres in cancer. The 
advent of publicly available databases that have molecularly catalogued cancer tissues (TCGA) 
facilitated a more nuanced assessment of gene expression signatures that display an 
overrepresentation of centromeric epigenetic factors. Furthermore, RNA-sequencing and ChIP-
sequencing are valuable tools by which centromere dysfunction can be epigenetically unraveled 
in the setting of malignancy. Underlying derangements in the centromeric locus compelled us to 
investigate the epigenetic components that traditionally occupy centromeric DNA. We thus 
leveraged a wide array of NGS-based molecular profiling techniques to investigate epigenetic 
destabilization of centromeres, using prostate cancer as our primary model system. We 
hypothesized that overexpression of centromeric factors such as CENPA has functional 
consequences to prostate cancer pathogenesis. 
 Mining transcriptomic data within a compendium of 10,848 RNA-sequencing libraries 
revealed widescale overexpression of CENPA in cancer tissue relative to lineage matched normal 
tissue. This finding corroborated previous reports of wide-scale overexpression of CENPA in 
cancer, though in much larger cohort sizes15–17. A more focused analysis within the prostate cancer 
tissue type cohort within this compendium demonstrated overexpression of a number of 
centromere/kinetochore proteins relative to normal prostate tissue, and further showed a successive 
increase of CENPA mRNA with disease progression, a finding that was validated at the protein 
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level in cell lines and tissue. Ontologic assessments of transcriptional signatures that correlate 
tightly with CENPA expression in prostate cancer tissue further revealed significant associations 
with proliferation, cell division, centromere, and kinetochore concepts, corroborating the notion 
that CENPA overexpression in prostate cancer is linked to cellular programs that govern cell 
division. Loss-of- and gain-of-function experimentation in cell lines revealed that CENPA 
modulation indeed affects proliferative phenotypes, where CENPA depletion impairs prostate 
cancer proliferation by altering flux through the cell cycle while overexpression of CENPA propels 
proliferation of benign prostatic epithelial cells. As seen previously in colon cancer cell lines, we 
demonstrate that in a cell line that overexpresses CENPA, we identify non-canonical binding 
across the genome to regulatory regions in close proximity to genes involved with nuclear 
architecture and DNA-replication, including the CENPA locus itself. Intriguingly, subsequent 
RNA-seq analysis on CENPA depleted cells reveals drastic changes in the transcriptional profile 
of prostate cancer cells. Integrative analysis between ChIP-seq and RNA-seq analysis indeed 
revealed an intersection between genes that are bound by CENPA and genes that are differentially 
expressed with CENPA depletion. Of note, this list of genes includes those that encode factors 
crucial for cell cycle, centromere, and kinetochore integrity. Collectively, our findings implicate a 
previously uncharacterized function for CENPA in regulating transcription of genes important for 
cell cycle, centromere, and kinetochore function when overexpressed in the setting of prostate 
cancer (Figure 4.1).  
 
Furthering our Understanding of Centromeres in Cancer 
The work outlined in this thesis presents a lens into what remains to be accomplished to 
more completely delineate the contribution of centromere genetics and epigenetics to the 
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pathogenesis of cancer. While we present a previously uncharacterized taxonomy of the molecular 
irregularities that arise within centromeres in neoplastic settings, much work is required to inform 
our understanding of the mechanisms that drive these changes in cancer. 
 
Genetics 
Revisiting publicly available genomics data can help us build new tools that can navigate 
repetitive regions within NGS datasets. A thorough dissection of the abundance of sequencing 
reads across TCGA samples that contain chromosome specific a-satellites would provide powerful 
corroboration for the PCR findings presented in this thesis. Cross-referencing these findings to 
known genetic anomalies within each sample has the potential to reveal mechanistic drivers that 
result in the heterogeneous losses observed in a-satellite copy number. Tools that can survey 
variation in a-satellites across large datasets like TCGA can be subsequently leveraged to evaluate 
transcription arising from centromeric loci from RNA-seq datasets. These tools can additionally 
be repurposed to prospectively and/or cross-sectionally evaluate additional non-neoplastic 
biologic and disease processes, including development, aging, and inflammation (Figure 4.2). 
Indeed, as we have shown previously, contractions in the centromere of chromosome 21 were 
associated with trisomy 21 in DNA samples from those afflicted by Down’s Syndrome, a widely 
known disease due to aberrant development2. Cancer is widely known to be associated with 
increased age, and thus evaluating centromeric content in a prospective cohort of individuals as 
they age in conjunction with the diseases they develop during the aging process, may shed light 
into whether centromeric contraction observed in malignancy is in reality a signature that arises 
due to aging. Oxidative stress due to reactive-oxygen species (ROS) tension in an inflammatory 
setting may also have a propensity to alter centromeric DNA in a manner that facilitates copy 
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number variation when comparing healthy cells to cells from an inflammatory milieu in tissue. 
The insights drawn from these sorts of inquiries can collectively further our understanding of how 
the genomics underlying this critical structure for cell division affect outcomes under any number 
of biological conditions. 
From a functional standpoint, advances in gene-editing technologies have augmented our 
ability to genetically manipulate regions of interest to gain a better understanding of their 
contributions to biology. CRISPR-Cas9 gene-targeting strategies that employ guide RNAs with 
sequence complementarity to chromosome specific a-satellites and/or HERV-K111 have the 
potential to unlock deeper comprehension of the role centromere genetics play in both in vitro and 
in vivo settings. Cre-Lox recombination systems activated by tissue specific factors can 
additionally enhance these insights by offering an orthogonal methodology to validate CRISPR-
Cas9 findings while simultaneously determining if tissue lineage affects phenotypes in cells/tissues 
devoid of chromosome specific a-satellites. Given our findings presented in this thesis, it is 
conceivable that selective deletion of a-satellites will have oncogenic effects, both in vitro and in 
vivo, phenotypes that can be readily assessed through examination of cell proliferation and cell 
cycle in cell culture and in tissue. To ascertain the mechanisms that underlie the losses in 
centromere material, one can conduct parallel loss-of-function experiments that selectively target 
effectors within one of the several DNA-repair pathways, to determine if dysfunctional DNA-
repair machinery result in the heterogeneous losses in centromeric DNA in cancer. Finally, the use 
of human artificial chromosomes (HACs) may clarify the debate surround necessity and 
sufficiency of the genetic and the epigenetic components of the centromere to cell division, with 




 There are two related but separate components of our epigenetic findings that would benefit 
from future cell biology and mechanistic assessments: 1) canonical centromere epigenetics and 2) 
non-canonical centromere epigenetics. 
Canonical 
The altered gene expression patterns linked to CENPA expression that we uncovered in 
prostate cancer are unlikely to be restricted to the prostate lineage. A handful of studies have 
investigated centromeric signatures within cancer datasets that, while not nearly as comprehensive 
as our findings, present trends that are indeed similar to patterns we present here16,18. Thus, a 
natural extension is to investigate the significance of each of the genes within these centromeric 
signatures (genes that encode members of the CCAN and KMN complex) to malignant phenotypes 
and identify potentially synergistic partners through combinatorial loss-of-function 
experimentation. Identifying the most promising genes to target through such a strategy can 
involve using biochemical approaches such as immunoprecipitation of CENPA from cancer tissue 
followed by mass spectrometry (IP-MS) to nominate strong interactors that maybe therapeutically 
actionable. As an example, in prostate cancer tissue, CENPA expression is tightly associated with 
expression of HJURP, the chaperone responsible for localizing CENPA to a-satellite DNA. The 
interaction between CENPA and HJURP that is dependent upon ubiquitination of lysine 124 on 
CENPA, can potentially be a druggable interface between two molecules important for the fidelity 
of cell division. Dual loss-of-function studies involving both CENPA and HJURP that demonstrate 
a synergistic reduction in cell proliferation would serve as an immediate prerequisite to 




 With regards to the localization defects of CENPA tied to its overexpression in cancer, 
additional work is necessary to separate the contributions of ectopic CENPA deposition from those 
of canonical CENPA function in prostate cancer. Complementation experiments involving genes 
that are both CENPA bound and differentially expressed with CENPA modulation will partly 
address the importance of non-canonical CENPA function to prostate cancer pathogenesis. 
Preliminary attempts at reversing the proliferation defects in CENPA-depleted cells with 
CDC25C, a cell cycle phosphatase both bound by CENPA and differentially expressed under 
CENPA-depleted conditions, did not show complementation, as the proliferation defect is likely 
polygenic. A combinatorial approach to complementation will be required to better distinguish the 
role ectopic CENPA binding plays in perpetuating malignant phenotypes. 
Reproducing the prostate cancer findings presented in this thesis through a similar 
integrative genomics approach in additional cancer types will provide necessary parallel validation 
of the importance of gene expression signatures linked to ectopic CENPA deposition. Furthermore, 
mechanistically interrogating the binding partners that drive this ectopic deposition through similar 
IP-MS approaches as described above may inform additional therapeutic development. Previous 
work suggests that distinct binding partners direct canonical and non-canonical CENPA 
localization, with canonical deposition requiring HJURP and non-canonical deposition requiring 
DAXX19. Carefully choosing cell line models that either express intermediate or high levels of 
CENPA will aid in determining whether CENPA levels determine binding capacity to these 
chaperone proteins, potentially through similar use of a doxycycline-inducible system. Finally, a 
wholistic understanding of centromeric derangements in cancer will require mechanistically 
linking the genetic findings of heterogenous a-satellite loss with the epigenetic findings involving 
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ectopic CENPA localization. CRISPR-Cas9 mediated or Cre-Lox recombination directed deletion 
of specific centromeric markers followed by CENPA ChIP-seq may provide insight into whether 




 The importance of centromeres to cell division underscores our motivation to study these 
structures in the context of malignancy. Centromeres are vital to coordinating the faithful 
segregation of chromosomes, providing the foundation for kinetochore assembly and spindle fiber 
recognition. Eukaryotic biology is thus dependent on this highly conserved process in order to 
maintain proper growth and development. Aberrant regulation and control of cellular growth and 
development provide the underpinnings for the development diseases of cell division, i.e. cancer. 
Highly repetitive sequences termed a-satellites arranged in a head-to-tail fashion across each 
human centromere however present methodologic challenges to evaluating their genomic structure 
and function. Moreover, epigenetic characterization of centromeric components in cancer has to 
date yielded an incomplete understanding of the role they play in driving cancer pathogenesis. We 
thus sought to comprehensively dissect the genetic and epigenetic components of centromeres in 
the context of malignancy through methodologies that provide insight into the changes that occur 
in cancer, while functionally characterizing a subset of these changes. We found anomalies in both 
the a-satellite and HERV-K111 rich genetic landscape as well as in CENPA expression and 
localization in the setting of cancer. Our data suggest that the findings reported in this thesis have 
broad implications to cancer genetics and cancer biology, as the anomalies in a-satellite copy 
number, sequence homogenization in HERV-K111, and the overexpression/ectopic localization of 
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CENPA are present in a number of cancers, described above and in the literature. A deeper 
understanding of centromere structure and function in cancer will thus give rise to the future 
development of novel therapeutic strategies that may have clinical utility across several cancer 
types. Future work that is focused on mechanistically characterizing as well as generalizing the 
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Figure 4.1: Schematic depiction of centromeric molecular alterations in cancer. Copy number 
alterations in the form of a-satellite deletions are observed across cancer types in both cell lines 
and tissue. CENPA, the H3 variant that traditionally occupies a-satellite DNA, ectopically binds 
gene regulatory elements, such as transcriptional start sites (TSS), of genes important for cell cycle 
progression, such as CDC25C, when overexpressed in cancer. Future studies are necessary to 
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Figure 4.2: Schematic outline of future directions with chromosome specific PCR assay. 
Widescale applications of rapid centromere-specific PCR approaches have the potential to 
markedly expand our understanding of numerous biologic and disease oriented processes. The 
collection of a-satellite consensus sequences we have produced through rapid PCR-approaches 
can be computationally compiled into a centromere-specific reference genome build. Tools that 
can parse NGS datasets such as TCGA genomic and transcriptomic libraries for these consensus 
sequences can corroborate our PCR findings in a high throughput fashion. These tools can be 
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main text; Mohamad Mourad helped conduct experiments; Mark H. Kaplan helped conduct 
experiments and helped analyze the results; Ilana Chefetz, Sami N. Malek, and Ronald 
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Padmanabhan, Javed Siddiqui, Monica Palande, Claire Wang, Brian Qian, Elizabeth Ward, Tara 
Tang, Scott Tomlins, Scott Gitlin, Maureen Sartor, Gil S. Omenn, Arul M. Chinnaiyan, and David 
M. Markovitz. For this chapter, Anjan Kumar Saha and David Markovitz designed the project and 
directed the experimental studies. Anjan Saha, Rafael Contreras-Galindo, Monica Palande, Claire 
Wang, Brian Qian, Elizabeth Ward, and Tara Tang helped conduct in vitro experiments. Yashar 
S. Niknafs, Matthew Iyer, Tingting Qin, Karthik Padmanabhan, Maureen Sartor, and Gil S. Omenn 
helped with sequencing analysis, and statistical analyses. Javed Siddiqui and Scott Tomlins 
coordinated biospecimens and performed pathology assessments. Scott Gitlin and Arul M. 
Chinnaiyan helped interpret results. Anjan Kumar Saha and David Markovitz wrote the text. 
 
CHAPTER 4 
 This chapter was written and conceived by Anjan Saha and edited by David Markovitz. 
